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Abstract 
The prevalence and mechanisms of aminoglycoside-resistance in 
Gram-negative bacteria in the Prince of Wales Hospital from 1989 to 1992 
were studied. The rate of gentamicin- or tobramycin-resistance was high, 
being 10% to 29% amongst the enterobacteriaceae, 8-12% in Pseudomonas 
aeruginosa, 26-29% in other Pseudomonas sp and 28-48% in Acinetobacter 
sp. The rate of netilmicin-resistance was much lower, being 8% or less in Ps. 
aeruginosa and enterobacteria other than Enterobacters but 16-30% in 
Enterobacters (which include Enterobacter sp, Citrobacter sp and Serratia 
sp), Acinetobacter sp and Pseudomonas sp other than Ps. aeruginosa. 
Amikacin-resistance was uncommon (0.8-4%) amongst most organisms 
except Acinetobacter sp and Pseudomonas sp of which 8-26% were resistant. 
Resistance of 360 aminoglycoside-resistant Escherichia coli, Klebsiella 
pneumoniae and Pseudomonas aeruginosa isolates tested to these four 
clinically-used aminoglycosides was in general of high level with MIC90S 
being 128 mg/L or higher. Most isolates were resistant to multiple 
aminoglycosides in very variable patterns. Using the phosphocellulose paper 
binding assay to characterize aminoglycoside-modifying enzymes (AMEs) 
produced by these isolates, it was found that 93% or more produced AMEs. 
AAC(3)-I was the commonest enzyme responsible for gentamicin-resistance 
in E. coli (54%) and K. pneumoniae (45%) while APH(3")-I was the next 
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commonest enzyme which was responsible for streptomycin-resistance 
(45%). Adenylating enzymes were rare. In contrast, APH(3')-I was the 
commonest enzyme produced by Ps, aeruginosa (93%) followed by other 
APH(3')-type enzymes, while both acetylating (23%) and adenylating (18%) 
enzymes were not commonly found. Genes encoding for AAC(3)-I and . 
AAC(3)-II were borne on transferable plasmids of 66 - 221 Kb in E. coli and 
2.8 - > 221 Kb in K. pneumoniae. All except two aminoglycoside-resistant 
E. coli and K. pneumoniae isolates tested harboured one to 11 plasmids in 
very variable profiles while only 24% of Ps, aeruginosa isolates harboured 
one to two plasmids. Thus, aminoglycoside-resistant E. coli and K. 
pneumoniae belonged to a heterogeneous population and there was no 
apparent outbreak of these two organisms during the study period. 
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Aminoglycosides are a large group of antimicrobial agents which are 
especially effective in treating Gram-negative bacterial infections. Since the 
introduction of streptomycin in the mid 1940s，many more aminoglycosides 
have been developed which have good bactericidal activity against Gram-
negative bacilli including Pseudomonas sp, apart from their antituberculous 
activity. However, their dose-related toxicity is a major concern amongst 
clinicians, who either have to limit their dosage or use other, presumably 
safer, classes of antibiotics. Despite their side-effects, they continue to be 
widely used in the therapy of serious infections. 
1. Structure 
Aminoglycosides are aminosugars glycosidically linked to 
aminocyclitol rings (Rinehart, 1969). The six-member aminocyclitol ring is 
either 2-deoxystreptamine, streptidine or others. Thus they are actually 
aminoglycosidic aminocyclitol antibiotics. Although spectinomycin is often 
included as an aminoglycoside, it contains no aminosugar and no glycosidic 
bond. However, "aminoglycoside" is the name commonly used to represent 
this group of antibiotics. 
2. Classification 
The aminoglycosides may be divided into two groups: the 2-
deoxystreptamines and the streptidine. The 2-deoxystreptamines can be 
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divided into two main subgroups: the 4,5-disubstituted deoxystreptamines (eg, 
neomycin) and the 4,6-disubstituted deoxystreptamines (eg, gentamicin 
tobramycin) (Table 1). The only member of the streptidine containing group 
that is of any importance in medicine is streptomycin. For 2-
deoxystreptamines, substituents on the deoxystreptamine ring are numbered 1 
to 6，while substituents on the amino sugar linked glycosidically to the 4-
position are numbered 1, to 6，and those on the 5- or 6-position ofthe 
deoxystreptamine ring are numbered 1” to 6”，etc. For the streptidine group, 
the carbon atoms of the streptidine ring are numbered 1 to 6，and of the other 
rings sequentially 1，to 6, and 1" to 6”，etc (Figures 1-3) (Davies, 1991). 
The linkage of different aminosugars and side-chain modification of the 
respective basic ring structures will generate different compounds. 
3. Mode of action 
Aminoglycosides inhibit bacterial protein synthesis by binding 
irreversibly to the bacterial 30S ribosomal subunit. The exact site of binding 
is at the interface between the smaller 30S ribosomal subunit and the larger 
50S ribosomal subunit. The site of binding may differ amongst the 
aminoglycosides, since there appears to be at least two different types of 
ribosomal binding, one unique to streptomycin and one shared by other 
aminoglycosides. The bound ribosomes become unavailable for translation of 
messenger RNA (mRNA) during protein synthesis, thereby leading to cell 
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Figure 3 4,6-disubstituted deoxystreptamine: the structure of amikacin 
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misreading of the genetic code, leading to production of nonfunctional 
proteins. 
Protein synthesis begins with the attachment of the small ribosomal 
subunit to a binding site on mRNA. The initiating transfer RNA (tRNA) then 
binds so that its anticodon pairs with mRNA codon, resulting in the formation 
of an initiation complex. The large ribosomal subunit then binds to the 
complex. This subunit possesses two RNA binding site: a peptidyl-tRNA site 
known as P site and an aminoacyl-tRNA site known as A site. The initiating 
tRNA resides in the P site. The mRNA codon down stream of the initiation 
codon is opposite the A site and is available for pairing with an aminoacyl-
tRNA having the appropriate anticodon. When the A site is occupied by the 
appropriate aminoacyl-tRNA, a peptide bond is formed. The ribosome then 
moves along the mRNA by one codon, placing the peptidyl-tRNA in the P 
site and freeing the A site. The A site is then occupied by the next 
aminoacyl-tRNA that has an anticodon appropriate for the mRNA codon now 
opposite that site, and the process continues leading to progressive 
polypeptide synthesis. The ribosomal binding site will be freed as the first 
ribosome moves down the mRNA and will be attached by a second ribosome 
to begin polypeptide synthesis. The association of a number of ribosomes 
with a single mRNA forms a polysome. 
The interface between the 30S ribosomal subunit and the 50S 
ribosomal subunit consists of mRNA binding sites and aminoacyl-tRNA 
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acceptor sites. The accurate translation of the RNA depends on the precise 
interaction between ribosomes, RNA, and the anticodon associated with each 
incoming aminoacyl-tRNA. The binding of aminoglycosides results in faulty 
codon-anticodon recognition, thus abnormal proteins are synthesized. This 
effect of aminoglycosides is less prominent with streptomycin and more 
prominent with 2-deoxystreptamines. 
The action of streptomycin is mainly on the breakdown of polysomes 
to monosomes thus preventing effective peptide bond formation and chain 
elongation. Besides, streptomycin-bound monosomes are abortive to the 
initiative complexes since effective initiation cannot occur. 
Transport of aminoglycosides into bacterial cells is an essential process 
leading to antibacterial action. This transport is an aerobic energy-dependent 
process which enables aminoglycosides to penetrate successfully into the 
bacteria, to accumulate in high concentrations and to reach the intracellular 
ribosomal binding targets. It is dependent on an electrochemical gradient that 
is generated during respiration or adenosine 5'-triphosphate (ATP) 
hydrolysis. The transport of aminoglycosides may also involve a transporter 
molecule to which aminoglycosides bind during the transport. The nature of 
this carrier molecule has not been defined but it seems likely that divalent 
calcium or magnesium binds to the same carrier since high external 
concentrations of calcium or magnesium prevent aminoglycoside transport. 
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Aminoglycosides are useful in antimicrobial chemotherapy since they 
do not bind to eukaryotic (including human) ribosomes and cells of most 
human organs are unable to transport them. Similarly, mitochondria cannot 
transport aminoglycosides even through mitochondrial ribosomes are sensitive 
to aminoglycosides. 
4. Types 
More than 23 aminoglycosides have been developed, however, not all 
of them are useful clinically because of their toxic side effects or minimal 
activity against most bacteria. Streptomycin, which belonged to the 
streptidine group, was isolated from Streptomyces griseus in 1943 and was 
introduced for clinical use in the following year (Schatz, Bugie & Waksman， 
1944; Waxman, 1949). The drug is very poorly absorbed from the intestinal 
tract, but is well absorbed after intramuscular, subcutaneous, or intrapleural 
injection (Simon, 1968). Streptomycin has been mainly used for the 
treatment of tuberculosis (Lietman, 1990)，and in conjunction with penicillin 
to treat Enterococcus faecalis endocarditis (Jawetz 8c Sonne，1966; Kirby, 
1970). 
Neomycins were the first of the 2-deoxystreptamine group to be 
discovered. They were isolated from strains of S. fradiae (Waksman & 
Lechevalier, 1949) and were composed of three compounds: neomycin A, B 
and C. Framycetin was isolated from S. lavendulae and was found to be 
identical to neomycin B which is also produced by strains of Micromonospora 
9 
(Wagman et al.，1973). Neomycin A (neamine) is the least active 
antibacterially of the three compounds, and neomycin B and C are 
substantially more active but more toxic. Neomycins are the most neuro- and 
oto-toxic ofal l aminoglycosides (Davia, Siemsen & Aderson, 1970). They 
were originally used as a second line drug for treating tuberculosis, but since 
deafness was a very common side-effect, they were mainly used as topical 
and oral drugs for superficial staphylococcal or Gram-negative bacterial 
infections (Trimble, 1969). 
Kanamycin was isolated from a strain of S. kanamyceticus in Japan 
(Ball, Gray & Murdoch，1978). This organism produces three closely related 
substances designated as kanamycin A，B and C. Kanamycin B is twice as 
active but twice as toxic as kanamycin A. Kanamycin C is significantly less 
active and more toxic than kanamycin A. Although kanamycin has similar 
antibacterial activity as neomycin, it is highly active against all species of 
Proteus. Kanamycin-resistance began to appear in staphylococci and many 
enterobacteria are now resistant to kanamycin. As a result, it has been 
replaced by the newer aminoglycosides. 
Gentamicin was isolated from S. purpurea (Weinstein et al., 1963). It 
contains several components such as A, B, B,, C and X Gentamicin A and 
gentamicin X are much less active than gentamicin C complex against 
Staphylococcus aureus and E. coli and almost no antipseudomonal activity. 
The overall activities of gentamicin B and B, are greater but they are as toxic 
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as gentamicin X. Gentamicin A and X are 20-50 times more inhibitory to 
Trichomonas vaginalis than is gentamicin C. Gentamicin X is also active 
against Entamoeba histolytica. P_Lactam antibiotics (penicillins and 
cephalosporins) are commonly prescribed in combination with gentamicin (or 
other aminoglycosides) due to their synergistic effects although the two agents 
frequently inactivate one another if mixed together in the same infusion bottle 
(McLaughlin & Reeves，1971). Gentamicin is active against most members 
of the family Enterobacteriaceae and has been one of the most widely used 
antibiotics in chemotherapeutic regimens against infections caused by Gram-
negative and Gram-positive bacteria in the late 1960's and early 1970's (Cox, 
1969). 
Tobramycin is an aminoglycoside which has been derived from S. 
tenebrarius and was first described in 1967. It is composed of six 
components (factors 1-6), all of which are active against staphylococci and a 
variety of enterobacteria and factors 2 and 6 are also active against 
Pseudomonas sp. Factor 6 has been shown to be the most active of the 
components (Black & Griffith, 1970) and developed under the name of 
tobramycin. 
Sisomicin is produced by S. myosensis/inyoensis and is structurally 
related to gentamicin CjA (Weinstein et al, 1970). It is less active than, but 
as toxic as, gentamicin and tobramycin (Drasar et al, 1976). Its derivative, 
5-episisomycin is more active since it is resistant to a number of 
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aminoglycoside-degrading enzymes (Waitz et al, 1978; Watanakunakorn, 
1978). 
Amikacin is a derivative of kanamycin A. It is active against Ps. 
aeruginosa (Kawaguchi et al., 1972) and many gentamicin-resistant 
organisms including Serratia marcescens (Reynolds, Hamilton-Miller & 
Brumfitt, 1974, Meyer et al., 1975，Kelly & Matsen，1976). It has been used 
successfully in treating serious Gram-negative infections (Tally et al., 1975， 
Howard et al., 1976). Toxicity is similar to that of other aminoglycosides. 
Netilmicin is the A^-ethyl derivative of sisomicin (Noone, 1984). Its 
activity is similar to that of gentamicin but it is less active against Serratia sp， 
Pseudomonas sp and Providencia sp (Briedis & Robson，1976; Kantor & 
Norden, 1977) and seems to be less toxic than other aminoglycosides (Luft, 
Yum & Kkit，1976). It has been used successfully to treat severe Gram-
negative bacterial infections (Edelstein & Meyer, 1978; Maigaard, Frimodt-
Mmier&Madsen，1978). 
Ribostamycin is one of the fermentation products of S. ribosidificus 
(Akita et al.，1970). It is not a very active compound since it can be 
degraded by several of the enzymes which are usually responsible for 
resistance to aminoglycosides in clinically-important bacteria. 
Butirosin is produced by Bacillus circulans (Tsukiura et al., 1973). It 
is substantially more active against aminoglycoside-resistant organisms 
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because it is much less susceptible to degradation by enzymes. However, it is 
very toxic so it is not used clinically. 
Spectinomycin was recovered from the fermentation products of S. 
spectabilic and S.flavopersicus (Oliver et al, 1962). It is mainly used for 
the treatment of infections caused by penicillin-resistant Neisseria 
gonorrhoeae. 
B. Mechanisms of aminoglycoside-resistance 
Bacterial resistance to aminoglycosides can occur by three different 
mechanisms: ribosomal resistance, impermeability or ineffective transport 
and enzymatic modification of the aminoglycoside. 
Ribosomal resistance to streptomycin is due to mutation in one specific 
protein in the smaller ribosomal subunit leading to loss of ribosomal binding 
to streptomycin and very high levels of resistance. This type of streptomycin 
resistance is very uncommon in Gram-negative bacilli. Ribosomal resistance 
to the 2-deoxystreptamine group of aminoglycosides also exists but requires 
multiple mutations. This suggests that more than one site is altered. This 
type of resistance is also very uncommon. 
Resistance due to decreased drug uptake is also uncommon. It 
involves genetic defects in bacterial electron transport or adenosine 
triphosphatase (ATPase) activity. As a result, mutants are defective in the 
transport of all aminoglycosides. The requirement of oxidative energy in the 
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transport of aminoglycosides also explains why anaerobes are much less 
sensitive to these antibiotics. 
The most common mechanism for aminoglycoside-resistance involves 
enzymes produced by bacteria which modify aminoglycosides. Genes 
encoding such aminoglycoside-modifying enzymes (AMEs) are usually borne 
on plasmids. These enzymes modify an aminoglycoside by combining it with 
an acetyl, adenyl or phosphoryl group at amino or hydroxyl groups, thereby 
rendering it inactive. A large number of enzymes have been identified each 
of which catalyzes the addition of one of the above mentioned groups onto a 
specific site on one or more aminoglycosides. 
C. Aminoglycoside-modifying enzymes 
AMEs are classified according to their types and sites of modification. 
Three classes are known: 0-phosphotransferases (APH), 0-
nucleotidyltransferases or adenylytransferases (ANT or AAD) and N-
acetyltransferases (AAC). The nomenclature of these enzymes is as follows: 
APH, AAD and AAC for the type of enzymatic modification; (3)，（2，），(2"), 
etc, for the site of modification; and I，II, III，etc, for unique resistance 
profiles. The reactions they catalyze are shown in Figures 4-6 and the site of 
modification of various enzymes are shown in Figure 7. AMEs exist in a 
number of isozymic forms ie, they act on the same site but vary in their 
substrate range as a result of difference in Km for various aminoglycosides. 
Thus, modification of a drug may not lead to a resistance phenotype. 
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Figure 4 Phosphorylation of aminoglycoside 
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Figure 5 Adenylylation of aminoglycoside 
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Figure 7 Enzymatic modification of aminoglycosides 
18 
1. Classification 
Table 2 shows the substrates and resistance phenotypes of AMEs. 
From this table, it can be seen that gentamicin- and netilmicin-resistance are 
predominantly due to an acetylating enzyme while kanamycin- or neomycin-
resistance is due usually to a phosphorylating enzyme. Amikacin-resistance 
is due to both adenylating and acetylating enzymes, 
i. Phosphotransferases 
These include APH(2"), APH(3'), APH(3"), APH(6) and APH(4). 
APH(2") is part of the bifunctional enzyme, AAC(6') + APH(2"), 
found only in Gram-positive bacteria. 
There are at least seven unique APH(3') enzymes which basically 
confer resistance to kanamycin and neomycin and variable resistance to 
butirosin, lividomycin, amikacin, isepamicin and gentamicin B (Mitsuhashi, 
1975; Shaw et al; 1993a). Both APH(3，)-I and APH(3')-II are widespread 
amongst members of the family Enterobacteriaceae and confer resistance to 
kanamycin but not to other routinely used aminoglycosides. These two 
enzymes can be differentiated since APH(3，）-I phosphorylates lividomycin 
while APH(3,)-II phosphorylates butirosin (Trien-Cuot & Courvalin，1986). 
APH(3')-III confers resistance to kanamycin, neomycin, paromomycin, 
ribostamycin, lividomycin, butirosin and gentamicin B. It is commonly found 
in Gram-positive bacteria although it has also been detected in Campylobacter 






















































































































































































































































































































































































































































































































































that of APH(3')-in except for susceptibility to lividomycin but resistance to 
amikacin and isepamcin. APH(3,)-VI is found mainly in Acinetobacter sp 
and rarely observed in other Gram-negatives (Shaw et al” l993a). The other 
APH(3,) enzymes are either not commonly found or their distribution 
amongst bacteria has not been examined. 
Both APH(3") and APH(6) confer resistance to streptomycin only 
while APH(4) confers resistance to hygromycin B only. Their distribution 
amongst bacteria has also not been determined. 
ii. Adenylytransferases 
Adenylytransferases include AAD(2"), AAD(3"), AAD(4'), AAD(6) 
and AAD(9). Only AAD(2") and AAD(4') confer resistance to tobramycin 
and dibekacin in addition to gentamicin, sisomicin and kanamycin or 
amikacin and isepamicin, respectively. While AAD(2") enzyme is found 
mainly in Gram-negative bacteria (Shaw et al, 1993a)，AAD(4')-I is 
restricted to Gram-positive bacteria (Miller et al., 1980) and AAD(4,)-II 
which was first discovered in 1981，has been mainly observed in Gram-
negative bacteria (Jacoby et al” 1990). Of AAD(3"), AAD(6) and AAD(9) 
which confer resistance to streptomycin and/or spectinomycin, only AAD(3") 
is commonly found in Gram-negatives while the other two are found in 




Four classes of A^-acetyltransferases which modify aminoglycosides in 
the 1-, 3-，6，- and 2,- amino groups have been identified (Benveniste & 
Davies, 1973; Mitsuhashi, 1975; Foster, 1983; Lovering, White 8i Reeves， 
1987). 
AAC(1) confers resistance to apramycin, lividomycin, paromomycin 
and ribostamycin although it also acetylates butirosin and neomycin (Hedges 
& Shannon，1984; Lovering, White & Reeves，1987). It was first detected in 
an apramycin-resistant E. coli veterinary isolate (Lovering, White & Reeves， 
1987). 
Five different AAC(3) resistance patterns have been identified. 
AAC(3)-I confers resistance to gentamicin and fortimicin (Brzezinska et al., 
1972; Shimizu et al., 1985) and is commonly found amongst members of the 
family Enterobacteriaceae. It is also found in Pseudomonas sp, Serratia sp 
and Acinetobacter sp. 
AAC(3)-II, previously designated as AAC(3)-V (Barg, 1988), confers 
resistance to gentamicin, tobramycin, netilmicin, sisomicin and three other 
aminoglycosides not clinically used (Shimizu et al., 1985). Since the 
sequences of genes encoding AAC(3)-II and AAC(3)-V are identical (Barg, 
1988; Vliegenthart, Ketelaar-van Gaalen & van de Klundert, 1989)，this 
enzyme has been renamed AAC(3)-II (Shaw et aL, 1993a). The other 
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AAC(3) enzymes also confer resistance to clinically important 
aminoglycosides but are rarely observed. 
The AAC(6') group of enzymes is of particular clinical significance, 
since it modifies aminoglycosides of therapeutic importance such as 
gentamicin, netilmicin, tobramycin, amikacin and sisomicin. Based on the 
resistance profiles specified by the enzymes, two types of AAC(6') have been 
distinguished: AAC(6，）-I which confers resistance to amikacin but not 
gentamicin and AAC(6')-H which confers resistance to gentamicin but not 
amikacin. AAC(6')-I is common amongst Gram-negative bacteria while 
AAC(6')-II is restricted to Pseudomonas sp (Miller et al., 1980; Shaw et al., 
1993a). 
AAC(2')-I is another rare enzyme which is found almost entirely in 
Providencia/Proteus and confers resistance to gentamicin, tobramycin and 
netilmicin (Shimizu et al., 1985). 
In summary, resistance to gentamicin, netilmicin and sisomicin is 
usually due to acetylating enzymes while that to tobramycin is due mainly to 
acetylating enzymes but may also be due to adenylating enzymes. Resistance 
to amikacin is due mainly to acetylating and adenylating enzymes while 
resistance to neomycin and kanamycin is due almost entirely to 
phosphorylating enzymes. Resistance to spectinomycin is due only to 
adenylating enzymes while that to streptomycin is due to two phosphorylating 
and two adenylating enzymes. 
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2. Genes encoding AMEs 
Genes encoding AMEs are usually located on plasmids. Many such 
genes have been cloned and their nucleotide sequences determined (Shaw et 
al., 1993a). 
Two genes aac(3)-Ia and aac(3)-lb have been identified which encode 
AAC(3)-I enzyme. aac(3)-Ia, also known as aacCl, was cloned from E. coli 
PS4221 and sequenced (Tenover et al., 1989) and was found in more than 
70% of strains which produced AAC(3)-I enzyme (Shaw et al., 1993a). 
aac(3)-Ib was cloned from Ps. aeruginosa STONE130 (Schwocho et al., 
1992) but its distribution amongst AAC(3)-I-producers has still to be 
determined. 
AAC(3)-II was previously known as AAC(3)-V. As nucleotide 
sequence analysis showed that genes encoding both AAC(3)-II and AAC(3)-V 
were identical (Allmansberger, Brau & Piepersberg，1985; Barg 1988; 
Vliegenhart, Ketelaar-van Gaalen & van de Klundert, 1989)，AAC(3)-V is 
renamed as AAC(3)-II to avoid confusion (Shaw et al., 1993a). 
There are three genes aac(3)-IIa, aac(3)-IIc and aac(3)-IIb which 
encode AAC(3)-II enzyme, the first two showing 97% sequence homology. 
aac(3)-IIa was cloned from Serratia marcescens (Vliegenhart, Ketelaar-van 
Gaalen & van de Klundert, 1989) and is the most common as it was present 
in more than 80% of isolates which produced AAC(3)-II. However, since it 
is almost identical to aac(3)-IIc, strains which carry the aac(3)-IIc would also 
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hybridize to the aac(3)-IIa probe. The third gene, aac(3)-IIb, was also 
cloned from S. marcescens (Rather et aL, 1992) and has 72% homology with 
aac(3)-IIa, but was rarely found in clinical isolates. 
Three genes encode AAC(3)-III, aac(3)-IIIa which was cloned from 
Ps, aeruginosa (Vliegenthart, Ketelaar-van Gaalen & van de Klundert, 1991)， 
and aac(3)-IIIb and aac(3)-IIIc from other Pseudomonas sp (Leal et al., 
1990; Shaw et al., 1993a). The nucleotide sequence of aac(3)-IIIc (Leal et 
al., 1990) and ant(2 ")-Ib was found to be identical. Besides the similarity of 
the proteins encoded by these genes, the resistance spectrum conferred was 
also identical. Thus it was concluded that the ant(2")-Ib gene was 
misclassified and should actually be an aac(3)-III gene. 
At least nine aac(6,)-I gene have been cloned (Shaw et al., 1993a). 
aac(6')-Ib was the most prevalent, followed by aac(6')-Ic. aac(6')-Ia and 
aac(6,)-ld were extremely rare. aac(6,)-Ie encodes a portion of the 
bifunctional enzyme AAC(6') + AHP(2") which was only found in Gram-
positive bacteria. aac(6)-Ifv/diS cloned from Enterobacter cloacae (Teran, 
Suarez & Mendoza, 1991)，aac(6')-Ig and aac(6')-lh from Acinetobacter sp 
and aac(6)-Ii from Enterococcus faecium (Costa et al., 1993). 
aac(6')-IIa, encoding AAC(6')-H, was cloned from Ps. aeruginosa 
(Shaw et al., 1989). However aac(6,)-IIa was 74% identical to aac(6,)-Ib so 
that there was cross hybridization between the aac(6,)-Ib and aac(6,)-IIa-
harbouring strains (Shaw et al., 1992). It was recently found that another 
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gene, aac(6’)-IIb，which did not hybridize to aac(6,)-Ib probe, was present 
amongst strains which produced AAC(6')-II enzyme (Shaw et al., 1993a). 
Although three genes encoding 2“-0-adenylyltransferase activity have 
been reported (Lee, Cleary & Gerding，1987)，only ant(2 ")-Ia gene was the 
commonest (Shaw et al., 1991; 1993b). ant(2 ")-Ib which was identical to 
aac(3)-IlI was very rare (Shaw et al., 1991) and another gene, not yet cloned, 
was thought to exist in those strains which produced AAD(2")-I but were 
ant(2 ")-Ia probe negative. 
An ant(4')-Ia probe had been developed which hybridized to less than 
90% of Gram-positive strains producing the AAD(4')-I enzyme (Shaw et al., 
1993b). Thus, probably more than one gene encoded this enzyme. 
Similarly, more than one gene encoded AAD(4,)-II since about 20% of 
strains producing this enzyme did not hybridize with an ant(4,)_IIa probe 
(Shaw etal.，1993b). 
Of the enzymes which conferred resistance to streptomycin and/or 
spectinomycin, AAD(3")-I was encoded by an ant(3 ")-Ia gene which was 
ubiquitous amongst Gram-negative bacteria (Shaw et al., 1991). AAD(6)-I 
was encoded by an ant(6)-Ia gene which was present in 80% or more of 
Gram-negative bacteria (Ounissi et al.，1990), either as a functional or cryptic 
chromosomal gene (Shaw et al.，1993a). AAD(9)-I was encoded by an 
ant(9)-la gene which was unique to Staph aureus (Murphy, 1985). 
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3. Applications 
It is important to study AMEs because determinations of the type and 
site of modification have allowed the design and synthesis of semisynthetic 
antibiotics which are not modified by the enzyme and therefore have a wider 
spectrum of activity. Apart from conferring aminoglycoside-resistance to 
bacteria, AMEs have been subjected to many practical uses. Before the 
advent of sophisticated technology, AMEs had been used for the assay of 
aminoglycosides in serum, thereby providing a rapid and inexpensive means 
of determining aminoglycoside concentration in the blood. This is 
particularly useful in patients who might develop the risk of toxicity due to 
inadequate excretion of aminoglycosides. Both the radioenzymatic assay 
(Haas & Davies, 1973; Shannon & Phillips, 1977) and radioimmunological 
assay (Lewis, Nelson & Elder, 1972; Stevens, Young & Hewitt，1975) had 
been used and they gave comparable results. Microbiological assay using 
sensitive strains had also been used but was a less rapid method (Sabath et 
al., 1971; Broughall & Reeves, 1975). However it had been particularly 
useful when unrelated antibiotics were present in the same sample as AMEs 
could be used to remove the aminoglycoside. Recently, AMEs have been 
used in the inactivation of aminoglycosides during measurement of their post 
antibiotic effect (den Hollander et al., 1996). 
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D. Prevalence of aminoglycoside-resistance 
Various reports from different parts of the world which presented data 
on the prevalence of aminoglycoside-resistance showed that in general E. coli 
isolates were usually susceptible to gentamicin. Other enterobacteria had 
different levels of resistance, and Pseudomonas sp other than Ps. aeruginosa 
were the most resistant organisms (Table 3). These studies also showed that 
tobramycin had similar activity as gentamicin, netilmicin was more active 
than these two aminoglycosides and amikacin was the most active 
aminoglycoside. 
A ten-year study from 1975 to 1984 in a hospital in London, UK 
showed that although gentamicin-resistance had appeared in a number of 
species by 1975, it remained rare in E. coli ( < 1 %) throughout the study 
period (Phillips, King & Shannon, 1986). Gentamicin-resistant klebsiellae 
constituted 8% of isolates by 1977 and remained almost unchanged in their 
frequency of isolation. Although Serratia sp were not frequently isolated, 
gentamicin-resistance in these organisms was first observed in 1979 and the 
level of resistance was found to be at 10-20%. Most Providencia sp were 
gentamicin-resistant but <5% ofthe other Enterobacteriaceae were resistant 
to gentamicin. Five percent or less of Ps. aeruginosa and Acinetobacter sp 
were resistant to gentamicin. On the whole, the level of tobramycin-
resistance was similar to that of gentamicin-resistance and amikacin-resistance 















































































































































































































































































































































































































































































































































































































































































































































































The prevalence of gentamicin-resistance in Riyadh in the Middle East 
was low, being less than 2% o f £ . coli and 10-25% of Ps. aeruginosa (Moaz, 
Shannon & Phillips，1989). 
Ofthe 239 enterobacteria isolated from urines between 1982 and 1983 
in Germany, only 4% were resistant to tobramycin and 0.4% to amikacin 
(Naber et al” 1990). The corresponding figures for 26 non-fermenters were 
23% and 8%. Only 3% of the 3415 enterobacteria isolated from blood 
cultures during 1983-85 were resistant to gentamicin or amikacin. Non-
fermenters were also more resistant with 14% of 925 isolates being resistant 
to gentamicin and 3% to amikacin. During 1986 and 1987, the frequency of 
resistance to gentamicin, tobramycin and amikacin of enterobacteria were 
higher, being 2-8%, 2-15%, and 1-19%, respectively, while that of Ps. 
aeruginosa was low, being 2-6%. 
Gram-negative bacteria isolated from blood cultures of patients in 
Austria during the period 1982-88 varied in prevalence of resistance to 
aminoglycosides (Mittermayer et al” 1990). Six percent or less of the E. coli 
isolates were resistant to gentamicin or tobramycin while resistance to 
netilmicin only appeared from 1987 onwards and resistance to amikacin 
decreased from 5% to nil in 1984 but increased to 3% in 1987. For other 
enterobacteria, there was a decrease in resistance to these four 
aminoglycosides from 1982 to 1988 while for the non-fermenters there was 
an increase in resistance except to tobramycin, 
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The resistance to aminoglycosides in Europe was monitored by the 
European Study Group on Antibiotic Resistance (1987). Twenty-nine 
laboratories in 12 countries were included in the 1984/85 study, and it was 
noted that aminoglycoside-resistance in blood and urine isolates was 
consistently higher in Southern Europe, being 31% but < 10% in isolates 
from Northern Europe (European Study Group on Antibiotic Resistance, 
1987). Amikacin-resistance was generally <6% and netilmicin-resistance 
< 10%. In 1987/88，37 laboratories in 14 countries participated in a similar 
study which investigated 3440 blood isolates (Dornbusch et al., 1990). Most 
of the 2162 Gram-negative bacilli were susceptible to gentamicin and 
netilmicin (88%), tobramycin (89%) or amikacin (91 %)• Similar to the 
previous study (European Study Group on Antibiotic Resistance, 1987)， 
resistance to these aminoglycosides was in general higher in Central or 
Southern Europe than in Northern Europe. 
In a study of 3068 strains of Enterobacteriaceae isolated from different 
patient specimens in nine general hospitals in France in 1988 and 1989，it was 
shown that they were largely susceptible to the aminoglycosides, with 5-6% 
being resistant to gentamicin, tobramycin or netilmicin and 1 % to amikacin 
(Boisivon et al., 1992). 
Whilst most studies dealt with the frequency of aminoglycoside-
resistance amongst bacteria, Gaynes and colleagues (1987) studied the 
susceptibility to aminoglycosides of ampicillin-resistant E. coli collected from 
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nine hospitals in the United States. They found that only 5% of these isolates 
were resistant to gentamicin, tobramycin, netilmicin or amikacin. 
Maes and Vanhoof (1992) studied the effect of amikacin usage on the 
epidemiology of aminoglycoside-resistance in a general hospital in Belgium. 
A total of 1988 and 6295 organisms were isolated in a 12-month pre-amikacin 
period and a 44-month post-amikacin period, respectively. The level of 
resistance in the pre-amikacin period was 15% to gentamicin, 16% to 
tobramycin, 14% to netilmicin and 6% to amikacin. Amikacin was 
subsequently the aminoglycoside of first choice during the following 44 
months. In the first 24 months of this phase, resistance to amikacin did not 
change significantly. Later, the level of amikacin-resistance rose significantly 
to up to 11 %，mainly due to the predominance of amikacin-resistant 
Enterobacter aerogenes. In contrast, there was a significant decrease in 
resistance to gentamicin (6%) and tobramycin (10%). Other workers also 
noted an increase in resistance to amikacin after indiscriminate use of this 
aminoglycoside (Cross, Opal & Kopecko，1983; Levine et al.，1985) and 
subsequent decrease in gentamicin- and tobramycin-resistance (Price et al.， 
1981; Betts et al.，1984; Gerding & Larson, 1985; Powell & Pincus，1987). 
However, it may be difficult to conclude from these studies that the use of 
amikacin was the only contributing factor as there were also important 
increases in the usage of other antibiotics especially third generation 
cephalosporins. 
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Toscano and colleagues (1991) examined the prevalence of 
aminoglycoside-resistance amongst 2000 clinical Gram-negative bacterial 
strains isolated between 1986 and 1990 in Catania, Italy. Gentamicin- and 
tobramycin-resistance amongst the coliforms were high, ranging from 15 to 
42%, while netilmicin- and amikacin-resistance were lower, being 0-23%. It 
is worth noting that all Arizona sp and Providencia sp were susceptible to 
netilmicin or amikacin while a high percentage of Serratia sp were resistant 
to all the four aminoglycosides tested. Resistance to these aminoglycosides 
was also high amongst Pseudomonas sp and other non-fermenters, being 31-
54% to gentamicin, 11-38% to tobramycin, 12-17% to netilmicin and 10-18% 
to amikacin. Thus in general, both netilmicin and amikacin had good activity 
against the Gram-negatives. Although aminoglycoside-resistance during the 
study period was high, the authors noted that there was an actual decrease in 
resistance as compared to the 1982-86 period. They attributed this to the 
decreased use of aminoglycosides particularly gentamicin and tobramycin, in 
the treatment of Gram-negative bacterial infections, leading to diminished 
selective pressure and thus probably the loss of plasmids carrying 
aminoglycoside-resistance genes. 
E. Methods for the determination of aminoglycoside-modifying enzymes 
The types of AMEs produced by an aminoglycoside-resistant organism 
can be determined by three main methods: examination of resistance 
phenotype (Davies, 1991)，phosphocellulose paper binding assay (Davies, 
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1991)，and hybridization with specific gene probes (Flamm et aL, 1993). 
Other methods include antibiotic inactivation and high performance liquid 
chromatography (HPLC) (Lovering, White & Reeves，1986a) but these are 
less popular. 
1. Examination of resistance phenotype 
The types of aminoglycosides which serve as substrates and thus 
leading to a resistance phenotype can be used to indicate the type of enzymes 
that may be present, van de Klundert and colleagues (1984) devised a 
stepwise determination scheme to correlate susceptibility to aminoglycosides 
with the presence of AMEs. This method compared inhibition zone 
diameters around commercially available sensitivity discs for six 
aminoglycosides with empirically established critical values which were 
characteristic of an enzyme group. The bacterial species were used as a 
criterion for those enzymes which were confined to these species. Table 4 
shows AMEs which can be identified by this scheme. 
Shimizu and colleagues (1985) determined the minimal inhibitory 
concentrations of selected aminoglycosides by agar or broth dilution for each 
strain and used these results to define aminoglycoside resistance patterns. 
However, the aminoglycosides chosen did not allow classification of 
APH(3'), AAD(3"), APH(3") and APH(6). Table 5 shows the resistance 
patterns of strains which produced different AMEs. Although examination of 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































of a drug by an AME may not lead to a resistance phenotype due to 
difference in Km of various substrates for a given enzyme. Besides, 
expression of a given enzyme can vary in different organisms. For example, 
presence of AAC(6') in Pseudomonas sp determines resistance to tobramycin, 
kanamycin, neomycin and sisomicin, but the same enzyme in E. coli 
determines resistance to kanamycin only (Davies, 1991). Another drawback 
of this approach is that it would be difficult to determine the type of enzyme 
if more than one are present in the same strain as the resistance phenotypes 
are often superimposed. 
2. Phosphocellulose paper binding assay 
This is in general the preferred method. In this assay, the enzyme, 
drug and a radioactively-labelled cofactor are incubated and the radioactive 
product assayed (Shannon, Phillips & King, 1978). Crude enzymes which 
are released from bacteria by sonication or passage through a French pressure 
cell can be used. Aminoglycosides are strongly basic compounds that are 
positively-charged so they tend to bind to phosphocellulose paper which is 
negatively-charged. The transfer of [^^C]acetate from [^^C]acetyl coenzyme 
A, [i4c]AMP from [^^C]ATP, or [^^P]phosphate from gamma-[^^ATP to 
the aminoglycoside (Figures 4-6) is measured. Unreacted cofactors will not 
bind since they are negatively-charged and will be washed off from the paper 
during the washing step but both modified (labelled) and unmodified 
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aminoglycosides remain bound. The radioactivity on the paper can be 
measured in a liquid scintillation counter. 
3. Hybridization with specific gene probes 
With the application of genetic engineering, several AME encoding 
genes have been cloned and sequenced. Probes have been developed which 
can be used to detect the presence of specific genes in bacterial populations 
by DNA-DNA hybridization. Although this seems to be a rapid and accurate 
method for determination of AMEs, more and more genes with no homology 
of nucleotide sequence but encode proteins with significant amino acid 
sequence similarities have been found (Please refer to Section C-2). That is, 
different genes can encode the same AME, and absence of hybridization with 
one probe does not indicate absence of that particular AME. Table 6 shows 
the probes that have been developed for the specific identification of genes 
encoding AMEs. The occurrence and distribution of aminoglycoside-
resistance genes could be determined using these probes. These probes are 
extremely useful in following the spread of resistance, where the resistances 
originated from and which genes are becoming more prevalent. 
As phosphotransferases are the most widely distributed of the AMEs, 
Young and colleagues (1985) developed two probes for differentiating 
APH(3')-I and APH(3')-H enzymes. These probes were sensitive and 
specific in identifying the AME-producing strains. Using the 











































































































































































































































































































































































































































































































































































































































































































































































































































































































greater extent than butirosin while the reverse is true for APH(3')-II. 
However, when the extent of modification of the two drugs is similar, the 
isolate tested would be assumed to contain genes for both APH(3')-I and 
APH(3')-n. Using these two probes, it was found that the assumption was 
not correct as only the APH(3,)-I but not the APH(3')-II probe hybridized 
with strains which were shown to produce both APH(3')-I and APH(3')-II by 
the phosphocellulose paper binding assay. 
Although these probes could detect the presence of APH(3，)-I and 
APH(3')-n enzyme in enterobacteria, they were less useful with Ps. 
aeruginosa as less than half of the isolates tested which were shown to 
produce these enzymes hybridized with the probes. The authors attributed 
these to the low copy numbers of genes encoding phosphotransferase activity 
in strains which did not hybridize with the probe or that more than one 
structural gene encoded each of these two enzymes in Ps. aeruginosa. 
A 2-Kb probe which hybridized only with organisms containing the 
AAD(2") gene was constructed (Groot-Obbink et aL, 1985). The probe 
hybridized with both transferable and non-transferable plasmids as well as 
with the chromosome, indicating that the gene is part of a transposon. It is 
therefore possible to study the mobility and distribution of this gene in clinical 
isolates regardless of its location. 
Shaw and colleagues (1991) used DNA hybridization to study the 
correlation between susceptibility profiles and presence of specific genes. 
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They found that most AMEs of Gram-negative bacteria were due to more 
than one gene, that the frequency of some genes varied for different 
organisms and that the frequency of some genes varied from country to 
country. There were also some genes that were species-specific, eg. aac(6')-
IIa gene is found only in Pseudomonas sp and aac(6')-Ic gene only in 
Serratia sp. 
Flamm and colleagues (1993) found that by using DNA probes specific 
for six aminoglycoside resistance genes and modified disk criteria, the disk 
diffusion patterns of isolates tested correlated with the probe results. 
Snelling and colleagues (1993) investigated the distribution of the 
aac(6')-Ic gene in Serratia sp and 16 other genera of Gram-negative bacteria 
using a nucleotide probe which was prepared from the cloned gene of a 
clinical S. marcescens isolate. Using this probe, it was possible to detect the 
presence of aac(6')-Ic gene in all 74 S. marcescens strains tested, irrespective 
of whether or not they displayed AAC(6')-I resistance profile. As this gene 
was only found in S. marcescens, it could also be used to distinguish this 
from S. iiquefaciens as these two species only differed in the L-arabinose 
fermentation which often gave false positive results in commerical 
identification systems. This study also showed that S. marcescens had the 
potential to become resistant to clinically-important aminoglycosides such as 
amikacin and netilmicin since all isolates carried the aac(6')-Ic gene. 
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4. Antibiotic inactivation 
The enzyme is incubated with an antibiotic and cofactors (ATP and 
acetyl coenzyme A) and aliquots are removed at various times and spotted 
onto a standard paper disk (Davies, 1991). The disk is then placed on a lawn 
of sensitive bacteria. A decrease in size of the zone of inhibition with time 
will indicate inactivation of antibiotic. Controls without enzyme, ATP or 
acetyl coenzyme A are included. However, a positive result of inactivation 
using ATP may indicate phosphorylation or adenylylation so that the modified 
antibiotic has to be isolated and then identified by chemical and physical 
studies. 
5. High performance liquid chromatography (HPLC) 
Lovering and colleagues used high performance liquid 
chromatographic method to identify aminoglycoside-acetylating enzymes 
(Lovering, White & Reeves，1984)，aminoglycoside-phosphorylating enzymes 
(Lovering, White & Reeves, 1986a) and individual acetylating or 
phosphorylating enzymes within a mixture (Lovering, White & Reeves, 
1986b) by determining their reaction products. Reaction products from the 
action of individual enzymes with butirosin, lividomycin and kanamycin 
(AAC enzymes) or lividomycin and sisomicin (APH enzymes) were 
characterized by HPLC analysis. The retention times were compared with 
those of reaction products from the action of enzyme combinations with these 
aminoglycosides and identification of enzymes were made. For each pair of 
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enzymes tested, the aminoglycosides used were those that acted as substrates 
for only one of the enzymes present so that one reaction product resulted. 
Thus, it was possible to correctly identify AAC(2') + AAC(3), AAC(2') + 
AAC(6), AAC(3) + AAC(6) and APH(2") + APH(3') using this method. 
Crude enzymes can be used. This does not seem to be a popular method as 
few workers attempted it for the determination of AMEs probably due to the 
expense of equipment and sophisticated techniques involved. 
F. Prevalence of aminoglycoside-modifying enzymes 
Table 7 shows the types of AMEs produced by different bacteria in 
different parts of the world. On the whole, AAC(3)-II was the commonest 
enzyme produced by enterobacteria while other enzymes varied in prevalence 
in different localities. Shimizu and colleagues (1985) studies the mechanisms 
of aminoglycoside-resistance of Gram-negative bacteria in the Far East, Chile 
and US and showed that individual organisms from different countries had 
different prevalence of AMEs. For Pseudomonas sp, most strains from Chile 
produced a 3-A^-acetyltransferase while those from the Far East usually 
contained 6‘-N-acetyltransferase. Pseudomonas sp from the US showed a 
wider distribution of resistance mechanisms. Approximately equal 
proportions of strains contained 2"-0-adenylytransferases, 6'-N-
acetyltransferases and 3-N-acetyltransferases. There were also 5-15% of 
strains from all these places which were resistant to all the aminoglycosides 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































be due to decreased uptake of aminoglycosides or impermeability. For 
enterobacteriaceae, 97% of strains from Chile contained a 3-N-
acetyltransferase while 82% of these from the US contained AAD(2"). 
About half of the strains from the Far East also had an AAD(2") enzyme. 
Thus, different aminoglycoside resistance mechanisms had emerged in the US 
and Far East which could be reflected by the differences in the prevalence of 
resistance to gentamicin, tobramycin and amikacin. It was also found that 
such differences were related to different aminoglycoside usage in these 
countries. 
In a study in the UK, about half of the 20 E. coli isolates tested 
produced an APH(3') and enzymes which phosphorylated or adenylated 
streptomycin while only one strain produced AAC(3)-I (Shannon, Phillips & 
King, 1978). Of 30 Klebsiella sp, more than half produced an enzyme which 
adenylated streptomycin while only one-tenth produced an enzyme which 
phosphorylated streptomycin. Two-thirds of these strains produced an 
APH(3,) and about 40% produced AAC(3)-I. AAD(2") was detected in only 
one strain. Of 44 isolates of aminoglycoside-resistant Ps. aeruginosa in 
another study in the UK, only 10 produced AMEs (Phillips, King & Shannon， 
1978). All these produced an APH(3') enzyme. Five produced AAC(3)-I, 
five an AAD(2") and four an AAC(6'). A few strains also produced 
streptomycin phosphotransferase and streptomycin adenylyltransferase. 
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AAC(3)-I was the enzyme responsible for most of the aminoglycoside-
resistance seen in Enterobacteriaceae in London, UK until 1977 (Phillips, 
King & Shannon，1986) except for AAC(2') which was common in 
Providencia sp and non-enzymatic resistance in E. coli. Subsequently, 
AAC(3)-II and AAD(2") became the most common mechanisms of 
resistance. In gentamicin-resistant Ps. aeruginosa isolated during 1974-77, 
the resistance was usually attributable to non-enzymatic mechanisms but in 
later years the resistance was more often caused by AAC(3)-I, AAC(6,) or 
AAD(2"). 
Enzyme production from a total of 357 Gram-negative bacteria studied 
in a European survey in 1984-85 was determined (European Study Group on 
Antibiotic Resistance, 1987). No enzymes were found in 155 of these 
organisms while AAC(3)-V was the commonest enzyme (31%) followed by 
AAC(6，)-II (15%) and ANT(2") (10%). Most isolates produced a single 
enzyme (90%) and the rest producing two enzymes. Of those isolates which 
produced two enzymes, AAC(3)-I + AAC(6')-I was commonest (13 isolates) 
followed by AAC(6')-I + ANT(2") (5 isolates). 
The most common aminoglycoside-modifying enzyme in enterobacteria 
isolated in Riyadh, the Middle East, was AAD(2") although Providencia sp 
always produced AAC(2') and Serratia sp was always associated with 
AAC(6') (Moaz, Shannon & Phillips, 1989). Enzymes were less commonly 
detected in Acinetobacter sp and Pseudomonas sp. AAD(2") was also the 
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most common enzyme found in Pseudomonas sp but was never found in 
Acinetobacter sp. In a small study of 18 isolates of E. coli and Klebsiella sp 
from Czechoslovakia and the United States, AAD(2") was the commonest 
enzyme detected while AAC(3) was also common amongst Czechoslovakian 
strains (Navarova et al.’ 1989). 
Aminoglycoside-modifying enzyme production by 224 Gram-negative 
bacilli isolated from blood cultures in Europe was studied (Dornbusch et al., 
1990). Seventy-eight of these showed no detectable enzyme. Of the enzymes 
produced by the remaining isolates, AAD(2") and AAC(3)-V were 
commonest (16% each), followed by AAC(6)-II (13%) and AAC(6)-I alone 
(13%) or with AAD(2") (10%). 
A group of workers studied the resistance mechanisms to 
aminoglycosides in Enterobacter cloacae isolated from 12 hospitals in 
Athens, Greece (Vatopoulos et al., 1992). Of the 90 strains tested, 72% 
were resistant to one or more of the aminoglycosides. Eight strains which 
were resistant to gentamicin, tobramycin, netilmicin and amikacin were 
further investigated. All these strains harboured transferable plasmids of 40-
120 Md coding for the aminoglycoside resistances. Six different 
aminoglycoside-modifying enzymes were detected of which AAD(3"), 
AAC(6,)-I, AAD(2") and APH(3') were commonest. 
Of the 380 Gram-negative strains selected for study, AAC(3)-V and 
AAC(6,)-I were the enzymes most commonly produced (23% and 18%, 
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respectively) before amikacin was used as the aminoglycoside of choice 
(Maes & Vanhoof，1992). There was an increase of strains producing 
AAC(6')-I alone or in combination with AAD(2") or 八八匸⑶ wMe there 
were less strains with AAC(3)-V which was mainly found in Ps. aeruginosa 
after amikacin use. 
A recent study on the resistance mechanisms of 179 aminoglycoside-
resistant strains of Enterobacteriaceae isolated in a hospital in Hong Kong 
showed that AAC(3)-V alone or with APH(3')-I or other modifying enzymes 
accounted for gentamicin-resistance in 97% of isolates (Ho et al； 1993). 
The distribution of aminoglycoside-modifying enzymes in 151 isolates 
of enterobacteria obtained from patients in a medical centre in the United 
States during 1976-1986 was determined by demonstration of resistance genes 
by DNA-DNA hybridization using fragment probes (Flamm et al., 1993). It 
was found that AAD(2") was the commonest enzyme which was present 
alone in 55 isolates and together with APH(3')-I in 74 isolates while 
acetylating enzymes were very uncommon. 
The commonest enzyme produced by aminoglycoside-resistant Serratia 
marcescens isolated in Mexico City was AAD(2") together with AAC(6,)-I 
and AAD(2") together with AAC(6')-I + APH(3')-I (Coria-Jimenez & Ortiz-
Torres, 1994). 
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G. Objectives of this study 
The main objectives of this study are: 
1 • To determine the prevalence of aminoglycoside-resistance of Gram-
negative bacteria in the Prince of Wales Hospital of Hong Kong from 
1989 to 1992; 
2. To determine the susceptibility ofE. coli, K. pneumoniae and Ps. 
aeruginosa to 12 aminoglycosides and their resistance patterns {these 
three organisms were chosen for study since they were the commonest 
Gram-negative bacteria isolated in our hospital (Ling & Cheng,1995)}. 
3. To characterize the aminoglycoside-modifying enzymes which are 
responsible for the resistances and to locate the encoding genes by genetic 
and molecular studies; and 
4. To investigate the epidemiology of these resistant isolates by plasmid 
profile analysis. 
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MATERIALS AND METHODS 
Materials 
A. Bacterial strains 
1. Standard strains 
Standard strains used as controls for antibiotic sensitivity testing or as 
recipient for transferability studies, those containing plasmids of known size 
and those producing known aminoglycoside-modifying enzymes are shown in 
Table 8. 
2. Clinical isolates 
Bacterial strains were isolated from specimens of patients in the Prince 
of Wales Hospital according to standard procedures (Lennette et al., 1992) 
and their susceptibility to antibiotics were tested by disk diffusion using the 
comparative method (British Society for Antimicrobial Chemotherapy 
(BSAC), 1991). They were stored on nutrient agar slants at room 
temperature before further study was performed. Culture and susceptibility 
results were entered into the hospital computer to generate reports to be 
distributed to the requesting wards. 
A total of 360 aminoglycoside-resistant strains of Escherichia coli 
(222), Klebsiella aerogenes (65) and Pseudomomas aeruginosa (73) isolated 
from 1989 to 1992 were studied. All were single patient isolates. Their 
identity was confirmed by the API 20E system (bioMerieux Sa, France). 
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Table 8 Standard strains 
For sensitivity testing _ _ _ _ _ _ = = 
=S=S=S^ =5S=^ ^^ =^ ==^ =^ =^ =^ =^ '^^ ^^ ^^ ^^ ^^ ^^ ^ 
Organism Reference number 
Y ^ “ ATCC 25922, NCTC 10418 
Ps. aeruginosa ATCC 27853，NCTC 10662 
Staph, aureus ATCC 25923, NCTC 6571 
For determination of plasmid size 
Molecular size (Kb) Plasmid Strain No* 
^ m 40R646 
98 TP125 40R268 
119 TP129 40R448 
221 TP116 28R823 
62 X (fi+ Fu) 48R626 
91 A (ff Ii) RT641 
For transferability studies 
Organism Genotype Plasmid Strain No" 
E. coU K12 Flac+rif - 释 
For determination of AMEs 
Organism® Enzyme produced Enzyme produced 
1 ^ AAC(3)-I 72091801 
Enterobacter cloacae AAC(3)I + APH(3') 110354 
Staph, aureus ANT(4' 4") E4037 
Staph, aureus APH(3,) ^ ^ 
ATCC: American Type Culture Collection 
NCTC: National Collection for Type Cultures 
*Kindly supplied by Dr. B. Rowe, Division of Enteric Pathogens, Central Public Health 
Laboratory, London, U. K. 
**Kindly supplied by Professor M. H. Richmond, Department of Bacteriology, 
University of Bristol, 2222 U. K. 
® Kindly supplied by Dr. J. A. van de Klundert and B. S. W. Ho 
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B. Antibiotics, media, chemicals and instruments 
All culture media, antibiotics, chemicals, buffers and equipment used 
in this study are listed in Table 9. Methods for the preparation of buffers are 
shown in the appendix. 
Methods 
A. Prevalence of aminoglycoside-resistance 
Daily culture and susceptibility results were analysed by the hospital 
computer and monthly reports of the distribution of non-duplicate organisms 
isolated and their susceptibilities to different antimicrobial agents were 
compiled by the hospital data centre. Data from the monthly reports were 
entered into a spreadsheet program (Lotus 123，Lotus Development 
Corporation, USA) and analysed to produce results of the prevalence of 
aminoglycoside-resistance in this hospital. Statistical analysis was performed 
with a chi-square test. 
B. Susceptibility testing 
Minimal inhibitory concentrations (MICs) of 12 aminoglycosides 
(gentamicin, tobramycin, netilmicin, amikacin, kanamycin, neomycin, 
sisomicin, lividomycin, butirosin, ribostamycin, spectinomycin and 
streptomycin) were determined by an agar dilution method (BSAC, 1991). 
Isosensitest (IST) agar plates containing serial two-fold dilutions of antibiotics 
were prepared by adding appropriate volumes of antibiotics to molten agar at 
60°C to achieve the required fmal concentrations. The range of 
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Table 9 List of materials and equipment used in this study (Cont'd) 
I Items Source 
Culture media 
Nutrient agar (NA) 
Nutrient broth (NB) 
Isosensitest (IST) agar 一 Oxoid, Basingstoke, England. 
Isosensitest (IST) broth 




Kanamycin, Neomycin 一 Sigma, St Louis, MO, USA 
Sisomicin, Lividomycin 
Butirosin, Ribostamycin 
Streptomycin, Spectinomycin ^ 
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Table 9 List of materials and equipment used in this study (Cont'd) 
Items Source 
Chemicals 
Absolute alchohol Merck, Frankfuther Strasse, Germany 
Agarose gel Sigma 
Adenosine 5'-triphosphate (ATP), Sigma 
disodium salt 
Boric acid Sigma 
Bromophenol blue Sigma 
Chloroform Merck 
Ethidium bromide Sigma 
Ethylenediaminetetraacetic acid (EDTA) Sigma 
Iso-amyl alcohol Merck 
Isopropanol Merck 
Phenol GIBCO BRL, Gaithersburg, MD, USA 
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Table 9 List of materials and equipment used in this study (Cont'd) 
Items Source 
Sodium acetate (NaAc) BDH，Poole, England 
Sodium dodecyl sulphate (SDS) BDH 
Sodium hydroxide (NaOH) BDH 
Tris-base Sigma 
Kits 
API 20E BioMerieux, SA, France 
Restriction enzymes 
^coRl, Promega Corporpation, Madison, Wisconsin, USA 
H/ndIII 
DNA markers 
Supercoiled DNA ladder, GIBCO BRL 
HMWl digest of X DNA 
Radioactive isotopes 
[y-^^P]-ATP, 
["c]Acetyl coenzyme A, Amersham, Buckinghamshire, U. K. 
[8_i4q_ATP 
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Table 9 List of materials and equipment used in this study (Cont'd) 
Equipment 
Multipoint inoculator Soniprep 150 MSE，England 
Heraeus Sepatech, Osterode, West 
Biofuge 15 and Biofuge 22R Germany 
nn Pharmacia LKB, Biotechnology, 
Liquid scintillation counter S4100 uppsala, Sweden 
High speed centrifuge CR20B3 Hitachi, Japan 
Microwave oven SMC Hong Kong 
New Brunswick Scientific, Co., Inc 
Shaker G2 Edison, N. J. USA 
Water-bath E3 HAAKE，Germany 
GNA 200 and GNA 100 gel apparatus Pharmacia LKB 
Bio-Rad, Laboratories Inc., Hercules, 
500/200 power supply California, USA 
Ultraviolet (UV) transilluminator Ultra-violet Inc., Cabriel，CA, USA 
Polaroid, Corporation Cambridge, 
Polaroid MP4 Land Camera Massachusetts, USA 
Red filter Toshiba, Japan 
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Table 9 List of materials and equipment used in this study (Cont'd) 
Others 
Polaroid 667 films Polaroid Corporation 
Microtitre plate Dynatech Laboratories Inc., Virginia, USA 
P 81 Ion Exchange Chromatography paper Whatman International Inc., Maidstone, 
England 
Scintillation cocktail Beckman Instruments Inc., Fullerton, CA, 
USA 
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concentrations tested was 0.12-128 mg/L. Overnight colonies were 
emulsified in saline to a turbidity which matched that of MacFarland 0.5 and 
a tenfold dilution of this was used as the inoculum. This was inoculated onto 
antibiotic plates using a multi-point inoculator (Denley) to give 10^ organisms 
per inoculation spot. Plates were incubated at 37�C for 18 h. The MIC of an 
antibiotic was taken as the minimum concentration which inhibited visible 
growth on the inoculation spot. 
C. Characterization of aminoglycoside-modifying enzymes (AMEs) 
AMEs were released from bacteria by sonication and their substrate 
profiles analysed by the phosphocellulose paper binding method (Shannon, 
Phillips & King，1978). 
1. Extraction of enzymes 
Overnight colonies growing on IST agar containing 4 mg/L gentamicin 
(or another aminoglycoside to which the organism was resistant at a 
concentration recommended by the National Committee for Laboratory 
Standards (NCCLS) (1990) as a breakpoint value for susceptible organisms) 
were inoculated into 30 ml Nutrient Broth No. 2 and grown overnight with 
shaking. Cells were pelleted by centrifuging for 25 min at 6,000 g using a 
high speed centrifuge (CR20B3, Hitachi) at 4�C，washed twice with 3 ml 1 M 
Tris buffer (pH 7.0)，and resuspended in 1 ml enzyme extraction buffer 
(Appendix). Cells were then sonicated in ice-cold environment using a 
sonicator (Soniprep) at 6 amp for five or six times each of 20 sec. Each 
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sonication was separated by a period of cooling on ice. Cell debris and 
unbroken cells were pelleted by centrifuging for 5 min at 12,000 g in a 
microcentrifuge (Biofiige 15). The supernatant containing crude enzyme was 
used immediately or stored in aliquots at -20°C. 
2. Substrate profile analysis by the phosphocellulose paper binding assay 
This was performed by incubating the crude enzyme preparation with 
an aminoglycoside and a radioactive cofactor in sterile wells of a microtitre 
plate in a 37�C waterbath for 30 min. Table 10 shows the amount of 
different components used for the detection of acetyltransferase, 
phosphotransferase and adenylyltransferase. Twelve aminoglycosides as 
mentioned in the section on "Susceptibility testing" (Section B) were used, 
and water in place of an aminoglycoside was used as the negative control, for 
each enzyme tested. All of the mixture in each well was pipetted onto pieces 
of phosphocellulose paper and allowed to air-dry. The pieces of paper were 
then washed three times each of about 1 min in hot water (80�C) and dried in 
an incubator at 37�C (about 1 h). Each piece of paper was then placed in a 
scintillation vial containing scintillation cocktail (Appendix) and the bound 
radioactivity was measured by a liquid scintillation counter (Wallac 1410) in 
counts per minute (cpm). Presence of an AME was defined by a radioactive 
count five-fold or greater than the count from a control using water instead of 
an aminoglycoside (Gaynes et aL, 1987). The types of AME were identified 
according to the substrate profile, ie, the aminoglycosides hydrolyzed, and 
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Table 10 Amounts of different components used in the phosphocelluIose paper binding assay for 
acetyltransferase, phosphotransferase and adenylytransferase 
AAC APH AAD 
^ ^ [1-14C]C0-A [y-"P]ATP~~ [8-"C]ATP 
Specific activity ^Ci/viM 2 - 10 - 3000 50 _ 60 
Concentration ofactivity 50 2000 50 
ViCi/ml 
Concentration nM/ul 10 0.67 1 
Total radioactivity uCi 50 250 50 
Dilution 1 ： 50 20 ul 50mM NaATP 1 ： 5 
+ 10 Vil [Y-32p]ATP 
and make up to 1ml 
with deionized water 
Reaction Mixture 
Aminoglycoside (20mg/l) ^1 10 10 10 
Enzyme vil 20 20 20 
Diluted cofactor ]A 10 ^ � 
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the resistance profile, ie aminoglycosides to which the organism is resistant 
(Table 11). 
D. Localization of resistance genes 
To determine the location of aminoglycoside-resistance genes in 
resistant organisms, both genetic and molecular studies were carried out. 
1. Genetic study 
This includes determination of the transferability of resistance. 
Resistance genes which can be transferred to another bacteria by conjugation 
are usually located on plasmids. This can be tested by preparing two 
logarithmic broth cultures of a resistant strain, the donor, and a sensitive 
strain, the recipient, and then incubating one at 37°C and the other at 28°C, 
both without aeration (Anderson & Lewk，1965a, b). The recipient strain, 
Jp995, is an E. coli K12 which has a chromosomal marker, rifampicin-
resistance (Table 8). A temperature of 28°C was used to detect temperature-
dependent transferability which is a property of Group H plasmids. One 
hundred microlitres of the neat, 10" -^, 10'^ - and 10'^-fold dilutions of the 
conjugation mixture were plated out on MacConkey agar containing 64 mg/L 
rifampicin (to which only the recipient was resistant) and another antibiotic to 
which the donor was resistant at a concentration recommended by the 
NCCLS (1990) as listed in Table 16. Only transconjugants, ie recipients 
which had received the resistance plasmids from the donor, could grow on 




















































































































































































































































































































































































































































































































































































































































































dilutions of the conjugation mixture were plated on plain MacConkey agar to 
yield recipient cells. The number of transconjugants per recipient cell was 
the transfer frequency. 
Ten colonies growing on each selective plate were tested for resistance 
to antibiotics to which the donor was resistant by the agar dilution method as 
decribed in the section on "Susceptibility testing" but using breakpoint 
concentrations recommended by the NCCLS (1990) as listed in Table 16. 
Any colony which grew in the presence of the antibiotic at the breakpoint 
concentration was regarded as resistant and deemed to have received the 
resistance from the donor. 
Crude enzymes were extracted from transconjugants which had 
received resistances from the donor and the types of AMEs determined as 
described in section C. The AMEs of the transconjugant should be the same 
as that of the donor. 
2. Molecular studies 
To determine the size of the resistance plasmids, crude plasmid extract 
was prepared from both the donor and the transconjugant and then separated 
on agarose gels electrophoretically. The size of plasmids can be estimated by 
comparing the relative mobility with that of plasmids of known molecular size 
(Meyers etal.’ 1976). 
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i. Preparation of crude plasmid extracts 
Plasmids were extracted by the method of Kado & Liu (1981). A 
loopful of cells grown overnight on nutrient agar was emulsified in 200 [d 
lysing solution (Appendix), heated at 55°C for 30 min in a waterbath, and 
extracted with an equal volume of phenol-chloroform solution (1:1，vol/vol). 
The mixture was centrifuged at 12,000 g for 5 min at 4 � C using a microftige. 
The upper aqueous phase was aspirated and used immediately for agarose gel 
electrophoresis or stored at 4°C for future use. 
ii. Agarose gel electrophoresis 
Plasmid DNAs were electrophoresed on 0.7% agarose gels using a 
horizontal gel apparatus (GNA 200). Agarose was melted in an appropriate 
volume of 0.5X TBE buffer (Appendix) using a microwave oven and a slab 
gel (20 cm x 14.5 cm) was prepared using the GNA 200 gel former. Crude 
plasmid extract (10 i^l) with tracking dye (2 i^l) (Appendix) was loaded in 
wells of the gel and was electrophoresed in a TBE buffer system (Greene et 
al., 1974) at 90 V for 5 h. Plasmids of known size were included in every 
gel. The gel was stained with ethidium bromide (0.5 ^ig/ml) for 25 min at 
room temperature, and plasmid bands were photographed under shortwave 
(254 nm) ultraviolet (UV) transillumination using a Land camera (Polaroid 




with an aperture of 11. Since the logarithm of the distance between the 
！ 
i 
plasmid band and the origin of the gel is inversely proportional to the size of 
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the plasmid, the distance travelled by plasmids was measured and the size 
estimated by reading off from a curve of plasmids of known size versus 
relative mobility or by a computer programme (Ling et al., 1987). 
E. Plasmid profile analysis 
Strains with the same number and size of plasmids, ie, identical 
plasmid profile, may belong to the same clone. To determine the plasmid 
profile of individual strains, plasmids from all strains tested were extracted, 
subjected to agarose gel electrophoresis, and the size estimated, as described 
in section D.2.ii. 
F. Plasmid fingerprinting 
Plasmids of the same size may not be identical. To demonstrate 
whether they are the same, restriction endonucleases are used to digest these 
plasmids and the restricted DNA fragments separated on agarose gels 
electrophoretically to generate plasmid fingerprints. Plasmids of the same 
size and have identical fingerprints are the same while those of the same size 
but of different fingerprints are different. For restriction enzyme digestion of 
plasmids, purified plasmids have to be used since the crude preparation 
i 
contains substances which are inhibitory to restriction endonucleases. 
1. Preparation of purified plasmid 
This was done by the alkaline lysis method (Sambrook, Fritsch & 
Maniatis, 1989). Cells were pelleted from 1.5 ml of an overnight broth 
culture using a microfuge at 12,000 g for 2 min, washed with 0.5 ml STE 
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buffer (Appendix) and resuspended in 100 i^l Solution I (Appendix). To lyse 
the cells, 200 fA of Solution II which contained sodium hydroxide and a 
detergent sodium dodecyl sulphate (Appendix) were added, mixed 
immediately and incubated for 5 min on ice. Solution III (Appendix) (150 |il) 
was added to neutralize the mixture and the whole was gently mixed by 
inversion (five times) and incubated for 5 min on ice. Cell debris was 
pelleted by centrifuging for 20 min at 12,000 g at 4°C using a microfuge. 
The supernatant was transferred to a fresh eppendorf tube. Two parts 
of absolute alcohol were added and incubated for 2 min at room temperature 
to precipitate plasmids. It was then centrifuged at 12,000 g for 5 min at 4°C. 
The DNA pellet was washed with ice-cold 70% alcohol and finally 
redissolved in 400 i^l distilled water. Organic extraction of DNA was done 
once with an equal volume of buffered phenol, twice with phenol-chloroform-
isoamyl alcohol (25:24:1) and once with chloroform-isoamyl alcohol (24:1). 
DNA was precipitated by adding 1/10 volume of 3 M sodium acetate (pH 
5.2) and two parts of ice-cold absolute alcohol and keeping at -70�C for 18 h. 
DNA was pelleted at 12,000 g for 15 min at 4°C, the pellet washed with 1 ml 
ice-cold 70% alcohol and redissolved in 50 i^l distilled water. 
2. Restriction endonuclease digestion of plasmids 
Plasmids were digested with EcoRl or Hindlll by adding 10 units of 
the enzyme (10 u/^il) to 10 t^l plasmid solution, 2 [d 10X enzyme buffer 
(Appendix), RNase to a final concentration of 20 ^ig/ml and distilled water to 
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a total volume of 20 [il. The mixture was incubated in a 3TC waterbath for 
18 h. Restriction fragments were separated electrophoretically as described 
in section D.2.ii but using 0.8% agarose gels. A higher concentration of 
agarose was used since restriction fragments which are smaller than plasmids 
will be separated better. Hindlll digest of the phage lambda was used as the 
size marker instead of plasmids since plasmids in the form of covalently-
closed circular DNA had mobilities different from those of linear DNA 
fragments. The size of the different restricted fragments was estimated as 
described in section D.2.ii to produce fingerprint for each plasmid. 
Plan to achieve objectives 
1. Prevalence of aminoglycoside-resistance. To determine the prevalence of 
aminoglycoside-resistance amongst Gram-negative bacteria in the Prince 
of Wales Hospital, data on the monthly distribution of single patient 
isolates and their antimicrobial susceptibilities supplied by the hospital 
data centre were entered in a spreadsheet programme and analysed. 
Two-hundred and twenty-two aminoglycoside-resistant isolates of E. 
coli, 65 K. aerogenes and 73 Ps. aeruginosa were randomly selected for 
study of their susceptibility to aminoglycosides, resistance mechanisms 
and epidemiology. 
2. Susceptibility to aminoglycosides. After the identity of the isolates was 
confirmed using the API 20E system, the minimal inhibitory 
concentrations of 12 aminoglycosides to the selected isolates were 
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determined by an agar dilution method. The aminoglycosides included 
four which were frequently used clinically to determine the level of 
resistance and eight which were rarely used therapeutically were included 
mainly to determine the mechanisms of resistance. 
3. Characterization of aminoglycoside-resistance mechanisms. AMEs were 
extracted from these isolates by sonication and then subjected to the 
phosphocellulose paper binding assay to determine the substrate profile of 
the enzymes. Together with the MIC and substrate profile results, the 
types of enzymes were determined. The location of encoding genes was 
determined by transferability studies and resistance plasmids were 
characterized by determination of molecular size. 
4. Epidemiology of aminoglycoside-resistance. In order to determine 
whether the resistant isolates belonged to a small number of clones due to 
intra-hospital spread, isolates were typed by plasmid profile analysis and 
plasmid fingerprinting. By these experiments, we will understand why 
aminoglycoside-resistance was prevalent in this hospital and how further 
development or spread of resistance can be controlled. 
72 
RESULTS 
A. Prevalence of aminoglycoside-resistant Gram-negative bacilli isolated 
in the Prince of Wales Hospital from 1989 to 1992 
Table 12 shows the prevalence of gentamicin-resistant Gram-negative 
bacteria isolated in the Prince of Wales Hospital from 1989 to 1992. An 
average of 18% E. coli were resistant to gentamicin. There was a significant 
increase (p < 0.01) of gentamicin-resistant E. coli from 15% in 1990 to 20% 
in 1991 and remained the same at 20% in 1992. Similarly, there was an 
increase in the percentage of Klebsiella sp that were resistant to gentamicin 
from 7% in 1990 to 12% in 1991 (p < 0.01) and 14% in 1992 (12% and 
14%, p > 0.05, not significant). Such increase was more prominent for 
Proteus sp. Only 9% and 10% were resistant to gentamicin in 1989 and 
1990，respectively, but 26% and 17% (p < 0.01) in 1991 and 1992, 
respectively, became resistant. As a result, the average incidence of E. coli 
and Proteus sp resistant to this aminoglycoside was approximately the same 
(18% and 16%, respectively). Amongst the enterobacteria, the Enterobacters 
(including Enterobacter sp, Citrobacter sp and Serratia sp) were the most 
resistant (average 26%, range 18-33%). There was also a significant increase 
of resistance from 18% in 1989 to 33% in 1991 (p < 0.01). 
An average of 12% oiPs. aeruginosa isolated from 1989 to 1992 were 
resistant to gentamicin. Although resistance increased from 12% in 1989 to 













































































































































































































































































































































Pseudomonas sp increased in resistance from 26% in 1989 to 50% in 1992 (p 
< 0.01). Gentamicin-resistant Acinetobacter sp also increased in incidence 
from 42% in 1989 to 53% in 1992 (p < 0.01). 
Approximately similar proportions of isolates were resistant to 
tobramycin during the period 1989-1992 (Table 13) as compared to those that 
were resistant to gentamicin although with minor variations. 10-29% of the 
enterobacteria, 8% Ps. aeruginosa, 26% other Pseudomonas sp, and 28% 
Acinetobacter sp were resistant to tobramycin (Table 13). The change in 
resistance rates was also similar, with more E. coli，Klebsiella sp, 
Enterobacters, Pseudomonas sp other than Ps. aeruginosa and Acinetobacter 
sp isolates being resistant in 1992 as compared to those in 1989 while less 
Proteus sp and Ps, aeruginosa isolates were resistant in 1992 than in 1989. 
Considerably less isolates were resistant to netilmicin than to 
gentamicin or tobramycin (Table 14). Four to five percent of E. coli, 
Klebsiella sp, and Proteus sp and 16% of Enterobacters were resistant. 
Although there was a decrease in resistance rates during 1990-1991 {5% to 
4% of E. coli (p > 0.05), 6% to 2% (p< 0.01) of Klebsiella sp and Proteus 
sp, 20% to 13% (p< 0.01) of Enterobacters}, the resistances increased again 
in 1992 so that there was in general little change. Only 8% of Ps. aeruginosa 
were resistant to netilmicin. This low resistance rate was due to a decrease 

































































































































































































































































































































































































































































































































































































































































Although the proportion of other Pseudomonas sp and Acinetobacter sp 
resistant to gentamicin, tobramycin or netilmicin was similar, less of the latter 
organisms were resistant to netilmicin in 1992 (16%) than in 1991 (21 %) (p 
< 0.05) or 1990 (33%) (p < 0.01). 
Much less isolates (1-4%) were resistant to amikacin than to the other 
three aminoglycosides except for Ps. aeruginosa (8%) and other 
Pseudomonas sp (26%) (Table 15). There was a significant increase in 
resistance of Enterobacters from 3% in 1991 to 6% in 1992 (p < 0.01). In 
contrast, there was a significant decrease in resistance for the same period for 
Ps. aeruginosa (9% to 5%, p < 0.01) and Acinetobacter sp (11 % to 5%, p 
< 0.01). 
B. Susceptibility to 12 aminoglycosides of aminoglycoside-resistant E. 
coli, K. pneumoniae and Ps. aeruginosa 
The susceptibilities of 222 aminoglycoside-resistant E. coli isolates to 
12 aminoglycosides are shown in Table 16. Ninety-eight percent and 96% 
were resistant to 1 mg/L and 4 mg/L gentamicin, respectively. The 
resistance in these isolates was of high levels, with MIC50 of32 mg/L and 
MIC90 of 128 mg/L. Ninety-nine percent and 41 % were resistant to 1 mg/L 
and 4 mg/L tobramycin, respectively; and 88% and 31% to 1 mg/L and 4 
mg/L netilmicin, respectively. Resistances to tobramycin and netilmicin were 
of a lower level than that to gentamicin, with MIC50S and MIC90S being 4 









































































































































































































































































































































Table 16 Susceptibilities of 222 aminoglycoside-resistant Escherichia coli isolated 
from patients in the Prince of Wales Hospital from 1989 to 1992 to 12 
aminoglycosides 
p ( .,. % resistant to breakpoints 
� g (mg/l) recommended by 
Anitbiotic Range MIC50 MIC90 NCCLS' BSAC^ 
Gentamicin 0.5 - >128 32 128 96 (4) 98 (1) 
Tobramycin 0.5 - 128 4 16 41 (4) 99 (1) 
Netilmicin 0.25 - 128 4 16 31 (4) 88 (1) 
Amikacin 0.5 - 128 1 2 1 (16) 4 (4) 
Kanamycin 1 - >128 8 >128 57 (4)' 57 (4)' 
Neomycin 0.5 - 128 1 64 23 (16/ - -
Sisomicin 0.25 - >128 64 >128 94 (4)5 - -
Lividomycin 2 - >128 8 >128 23 (16)^  - -
Butirosin 0.5 - 128 2 4 2 (16, - -
Ribostamycin 1 - >128 4 >128 27 (16)^  - -
Streptomycin 2 - >128 64 >128 81 (16)' - -
Spectinomycin 4 - >128 128 >128 95 (16)6 . -
1 NCCLS: National Committee for Clinical Laboratory Standards (1990). 
2 BSAC: British Society for Antimicrobial Chemotherapy (1991). 
3 Breakpoint value recommended by NCCLS is 6 mg/l. 
4 Breakpoint value calculated using the BSAC formula. 
5 From : Navarova et al. (1989). 
6 Not defined by either NCCLS or BSAC. 
80 
and 16 mg/L amikacin, respectively, and only 0.5% with MICs of 128 mg/L. 
The other eight aminoglycosides were tested for the purpose of characterizing 
the aminoglycoside-modifying enzymes produced. More than 90% of the 
isolates tested were resistant to 4 mg/L sisomicin, and 23-57% to 4 mg/L 
kanamycin or 16 mg/L neomycin. Two percent were resistant to 16 mg/L 
butirosin and 23% and 27% to 16 mg/L lividomycin and 16 mg/L 
ribostamycin, respectively. More than 80% were resistant to 16 mg/L 
streptomycin or spectinomycin. 
Table 17 shows the resistance patterns of these isolates. All were 
resistant to at least two, and one was resistant to 11，aminoglycosides. Most 
of the isolates were resistant to four, three or five aminoglycosides (24%, 
19% and 17%, respectively) while approximately equal proportions were 
resistant to six or eight (12% and 10%, respectively). There were a total of 
54 resistance patterns. GSisSSp was the commonest resistance pattern (20%), 
followed by GSisSp (11 %)，GTbNetSisSSp (9%), GKNSisLivRibSSp (8%) 
and GTbSisSSp (7%). 
Table 18 shows the susceptibility of 65 aminoglycoside-resistant K. 
pneumoniae to 12 aminoglycosides. All were resistant to 1 mg/L or 4 mg/L 
gentamicin. Most of these had high level resistance with MIC50 of 64 mg/L 
and MIC90 of 128 mg/L. About half were resistant to 4 mg/L tobramycin 
(66%) or 4 mg/L netilmicin (52%). The resistances were of a lower level 
with MIC50S and MIC90S being 8-32 mg/L. Only one isolate was resistant to 
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Table 17 Resistance patterns of 222 aminoglycoside-resistant E. coli 
Isolates Total 
No. of 
Resistances Resistance Patterns* No. (%) (%) 
2 5 (2) 5 (2) 
3 GSisSp 25 (11) 
Other 17 (8) 42 (19) 
4 GSisSSp 45 (20) 
Other 9 (4) 54 (24) 
5 GTbSisSSp 15 (7) 
Other 23 (11) 38 (17) 
6 GTbNetSisSSp 20 (9) 
Other 7 (3) 27 (12) 
7 16 (7) 16 (7) 
8 GKNSisLivRibSSp 17 (8) 
Other 5 (2) 22 (10) 
9 10 (5) 10 (5) 
10 7 (3) 7 (3) 
11 GTbAkKNSisLivButRibSSp 1 � 1 � 
T o t a l 2 2 2 ( 1 0 0 ) 2 2 2 ( 1 0 0 ) 
* Abbreviations as in Table 11 
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Table 18 Susceptibilities of 65 aminoglycoside-resistant KlebsieUa pneumoniae 
isolated from patients in the Prince of Wales Hospital from 1989 to 1992 
to 12 aminoglycosides 
MIC (m /1) % resistant to breakpoints (mg/l) 
^ g recommended by 
Anitbiotic Range MIC50 MIC90 NCCLS' BSAC^ 
Gentamicin 8 - >128 64 128 100 (4) 100 (1) 
Tobramycin 1 - >128 8 32 66 (4) 96 (1) 
Netilmicin 0.25 - >128 8 16 52 (4) 83 (1) 
Amikacin 0.5 - 32 1 2 2 (16) 6 (4) 
Kanamycin 2 - >128 >128 >128 80 (4? 80 (4)^  
Neomycin 1 - >128 16 64 42 (16)^  - -
Sisomicin 1 - >128 32 >128 93 (4)^  - -
Lividomycin 4 - >128 >128 >128 62 (16)^  - -
Butirosin 1 - 64 1 2 2 (16/ - -
Ribostamycin 2 - >128 >128 >128 60 (16)6 - -
Streptomycin 2 - > 128 32 > 128 80 (16)' - -
Spectinomycin 8 - >128 >128 >128 88 (16)^  - -
1 NCCLS: National Committee for Clinical Laboratory Standards (1990). 
2 BSAC: British Society for Antimicrobial Chemotherapy (1991). 
3 Breakpoint value recommended by NCCLS is 6 mg/l. 
4 Breakpoint value calculated using the BSAC formula. 
5 From : Navarova et aL (1989). 
6 Not defined by either NCCLS or BSAC. 
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16 mg/L amikacin although four were resistant to 4 mg/L. More than 90% 
of the isolates tested were resistant to sisomicin, and 40-80% to kanamycin or 
neomycin. Only one isolate was resistant to butirosin (16 mg/L) while 60% 
or more were resistant to lividomycin (16 mg/L) or ribostamycin (16 mg/L). 
Eighty percent or more isolates were resistant to streptomycin (16 mg/L) or 
spectinomycin (16 mg/L). These isolates were resistant to two to 10 
aminoglycosides (Table 19). Only two resistance patterns were more 
commonly found, GTbKNSisLivRibSSp (11 %) and GTbNetSisSSp (9%) 
while the others were only found in one to four isolates. 
Table 20 shows the susceptibilities of 73 aminoglycoside-resistant Ps. 
aeruginosa to 12 aminoglycosides. Ninety-six percent were resistant to 4 
mg/L gentamicin. Most of these had high level resistance with MIC50 and 
MIC90 >128 mg/L. Similar proportions of isolates were resistant to 4 mg/L 
tobramycin (83%) and 4 mg/L netilmicin (95%). The resistances were also 
of a high level with MIC50S and MIC90S being 64 mg/L - >128 mg/L. Twenty 
percent of isolates were resistant to 16 mg/L amikacin. All were resistant to 
4 mg/L kanamycin but only 67% to 16 mg/L neomycin. More than 80% 
were resistant to sisomicin, lividomycin and butirosin and all were resistant to 
ribostamycin, streptomycin and spectinomycin except one strain that was 
sensitive to 16 mg/L streptomycin. 
All isolates were resistant to seven to 12 aminoglycosides (Table 21). 
Most were resistant to 11 aminoglycosides (32%) followed by those resistant 
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Table 19 Resistance patterns of 65 aminoglycoside-resistant K. pneumoniae 
Isolates Total 
No. of 
Resistances Resistance Patterns* No. (%) (%) 
2 ^ 1 � 1 � 
3 3 (5) 3 (5) 
4 7 (11) 7 (11) 
5 6 (9) 6 (9) 
6 GTbNetSisSSp 6 (9) 
Other 8 (12) 14 (22) 
7 8 (12) 8 (12) 
8 7 (11) 7 (11) 
9 GTbKNSisLivRibSSp 7 (11) 
Other 8 (12) 15 (23) 
10 4 (6) 4 (6) 
I 
Total 65 (100) 65 (100) 
* Abbreviations as in Table 11 
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Table 20 Susceptibilities of 73 aminoglycoside-resistant Pseudomonas aeruginosa 
isolated from patients in the Prince of Wales Hospital from 1989 to 1992 
to 12 aminoglycosides 
一 ^ , ,1� % resistant to breakpoints (mg/l) 
MIC (mg/l) recommended by 
Anitbiotic Range MIC50 MIC,p NCCLS^ BSAC^ 
Gentamicin 4 - >128 128 >128 96 (4) 100 (1) 
Tobramycin 1 - >128 64 128 83 (4) 92 (1) 
Netilmicin 2 - >128 >128 >128 95 (4) 100 (1) 
Amikacin 2 - >128 8 128 20 (16) 70 (4) 
Kanamycin 64 - >128 >128 >128 100 (4f 100 (4)4 
Neomycin 4 - >128 32 >128 67 (16)' - _ 
Sisomicin 1 - >128 128 >128 83 (4 , - -
Lividomycin 16 - >128 64 >128 99 (16)' - _ 
Butirosin 8 - >128 64 >128 84 (16)' - _ 
Ribostamycin > 128 - > 128 > 128 > 128 100 (16)' - -
Streptomycin 8 - >128 128 >128 99 (16)' - -
Spectinomycin 64 - > 128 > 128 > 128 100 (16)' - -
1 NCCLS: National Committee for Clinical Laboratory Standards (1990). 
^BSAC: British Society for Antimicrobial Chemotherapy (1991). 
3 Breakpoint value recommended by NCCLS is 6 mg/l. 
4 Breakpoint value calculated using the BSAC formula. 
5 From : Navarova et al. (1989). 
6 Not defined by either NCCLS or BSAC. 
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Table 2 1 Resistance patterns of 7 3 aminoglycoside-resistant Ps. 
aeruginosa 
I 1 Isolates Total 
R e s i l l e s Resistance Patterns* No. (%) � 
7 NetKLivButRibSSp 1 � ^ � 
8 5 (7) 5 (7) 
9 GTbNetKSisLivRibSSp 6 (8) 
Other 8 (11) 14 (19) 
10 GTbNetKSisLivButRibSSp 13 (18) 
Other 6 (8) 19 (26) 
11 GTbNetKNSisLivButRibSSp 21 (29) 
Other 2 (3) 23 (32) 
12 GTbNetAkKNSisLivButRibSSp H (15) 11 (15) 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
* Abbreviations as in Table 11 
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to 10 (26%), nine (19%) and 12 (15%). GTbNetKNSisLivButRibSSp was 
the commonest pattern, exhibited by 29% of isolates, followed by 
GTbNetKSisLivButRibSSp (18%) and resistance to all 12 aminoglycosides 
tested (15%). 
C. Aminoglycoside-modifying enzymes (AMEs) produced by E. coli, K. 
pneumoniae and Ps. aeruginosa 
Table 22 shows the AMEs produced by 222 aminoglycoside-resistant 
E. coli isolates tested. The identity of the AMEs was inferred from 
susceptibUity (MICs) results and substrate profiles determined by the 
phosphocellulose paper binding assay according to Table 11. All except 16 
isolates (7%) produced detectable enzymes. Approximately equal proportion 
of isolates produced one or two enzymes (40% and 42%, respectively) while 
9% produced three enzymes. Only three isolates produced four enzymes. 
The commonest enzyme detected was AAC(3)-I (54%) which conferred 
gentamicin-resistance, followed by APH(3，，)-I (45 %) which conferred 
streptomycin-resistance and AAC(3)-II (23%) which conferred gentamicin-, 
netilmicin-, and tobramycin-resistance. APH(3')-I, which conferred 
kanamycin- and neomycin-resistance, was produced by 16% of isolates. 
AAD enzymes were rarely found and were detected in 8% of isolates. Only 
two types of AAD enzymes were detected, AAD(3")(9) which conferred 
streptomycin- and spectinomycin-resistance was found in 10 isolates and 
AAD(6)-I which conferred streptomycin-resistance was found in eight 
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Table 22 Aminoglycoside-modifying enzymes (AMEs) produced by 222 E. coli strains 
isolated from the Prince of Wales Hospital from 1989 to 1992 
AMEs 
^ “ ~ " T ^ No (%) Total (%) 
0 NIL 16 (7) 16 (7) 
1 AAC(3)-I 51 (23) 
AAC(3)-II 19 (9) 
APH(3")-I 11 (5) 
^ ~ ~ “ ^ ~ ~ 7 (3) 88 (40) 
2 AAC(3)-I + APH(3，，)"I 40 (18) 
AAC(3)-II + APH(3")-I 18 (8) 
APH(3')-I + APH(3")-I 6 (3) 
Other 30 (14) 94 (42) 
3 AAC(3)-I + APH(3')-I + APH(3")-I 8 (4) 
^ 12 � 20 (9) 
4 AAC(3)-I + APH(3')-I + APH(3")-I + AAD(6)-I 1 (0.5) 
AAC(3)-II + APH(3')-I + APH(3")-I + AAD(3")(9) 1 (0.5) 
AAC(3)-II + APH(3')-I + APH(6)-I + AAD(3")(9) 1 (0.5) 3 (1) 
Total 222 (100) 222 (100) 
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isolates. Most isolates produced AAC(3)-I alone (23%) or in combination 
with APH(3")-I (18%), followed by those which produced AAC(3)-II alone 
(9%) or in combination with APH(3")-I (8%). Other isolates produced a 
combination of these and other enzymes. 
Table 23 shows the AMEs produced by 65 aminoglycoside-resistant K. 
pneumoniae isolates tested. Only two isolates did not produce any detectable 
enzyme. Most isolates (45%) produced two enzymes followed by those 
which produced only one enzyme (28%). There was one isolate which 
produced four enzymes. AAD enzymes were detected in 10 isolates (15%). 
Both APH(3")-I and AAC(3)-I were the commonest enzymes, being 
detected in 45% of isolates, followed by APH(3')-I in 37% and AAC(3)-II in 
35%. 
Most strains produced AAC(3)-I alone (14%) or in combination with 
APH(3")-I (12%). AAC(3)-II was produced as a single enzyme in six 
isolates (9%) while five isolates each (8%) produced AAC(3)-II and 
APH(3")-I, AAC(3)-II and APH(3，)-I and AAC(3)-I, APH(3')-I and 
APH(3")-I. 
Table 24 shows the different types of AMEs produced by 73 
aminoglycoside-resistant Ps. aeruginosa isolates tested. All except two 
isolates produced one to five detectable enzymes. About half of the isolates 
(46%) produced two and 30% produced three enzymes. Three isolates 
produced five enzymes. APH(3')-I was the commonest enzyme detected 
90 
Table 23 Aminoglycoside-modifying enzymes (AMEs) produced by 65 KlebsieUa 
pneumoniae strains isolated from the Prince of Wales Hospital from 1989 to 
1992 
AMEs 
No. !Type ^ No (%) Total (%) 
~ 7 " NIL 2 _ ( ^ 2 _ ^ 
1 AAQ3)-I 9 (14) 
AAC(3)-II 6 (9) 
Other 3 _ ( 5 ) 18 (28) 
2 AAC(3)-I + APH(3'>I 8 (12) 
AAC(3)-II + APH(3>I 5 (8) 
AAC(3)-II + APH(3'H 5 (8) 
APH(3')-I + APH(3")-I 4 (6) 
^ ‘ 7 (11) 29 (45) 
3 AAC(3)-I + APH(3')-I + APH(3")-I 5 (8) 
^ 10 ( � 15 (23) 
4 AAC(3)-II + APH(3')-I + APH(3")-I + AAD(6)-I 1 � 1 � 
Total 65 (100) 65 (100) 
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Table 24 Aminoglycoside-modifying enzymes (AMEs) produced by 73 Pseudomonas 
aeruginosa strains isolated from the Prince of Wales Hospital from 1989 to 
1992 
AMEs 
No. Type No (%) Total (%) 
0 NIL 2 (3) 2 (3) 
1 APH(3')-I 4 (6) 
Other 1 (1) 5 (7) 
2 APH(3')-I + APH(3')(5")-III 18 (25) 
APH(3')-I + APH(3')-VI 6 (8) 
APH(3')-I + APH(3")-I 6 (8) 
Other 4 (6) 34 (46) 
3 APH(3')-I + APH(3')(5")-III + APH(3")-I 10 (14) 
Other 12 (16) 22 (30) 
4 7 (10) 7 (10) 
5 3 (4) 3 (4) 
Total 73 (100) 73 (100) 
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(93%), followed by APH(3，)(5，，)-III (53%) and APH(3")-I (40%). AAC-
type enzymes were produced by only 17 (23%) and AAD-type by 13 (18%) 
isolates. Most isolates produced APH(3')-I and APH(3，)(5，，)-III (25%), and 
APH(3')-I, APH(3')(5")-ni and APH(3，，)-I (14%). Six isolates (8%) each 
produced APH(3')-I and APH(3，)-III，and APH(3,)-I and APH(3")-I. 
D. Plasmid profile analysis 
Table 25 shows the plasmid profiles of 193 E. coli isolates which 
survived for the study. All but two isolates harboured one to 11 plasmids of 
1.2 - > 221Kb. The majority of isolates (85%) harboured one to six 
plasmids. There were no predominant plasmid profiles amongst these 
isolates. Some of the plasmid proffles are shown in figures 8 and 8-1 • 
Plasmids of 76, 98 and 118 Kb were found in more than one isolate. 
Digestion of these plasmids with Ecom or HmdIII showed that they were not 
identical as revealed by their varied restriction patterns (Figures 9 & 10). 
All 58 K. pneumoniae isolates tested harboured one and up to eight 
plasmids. Most isolates (43%) harboured two plasmids, only one isolate 
harboured eight plasmids and the rest (55%) harboured one, three or four 
plasmids (Table 26). As with E. coli, plasmid profiles of K. pneumoniae 
were varied with no predominance of a particular profile (Fig 11). 
Only 15 (34%) out of 63 Ps. aeruginosa isolates harboured one to two 
plasmids of 1.3 - 119 Kb (Table 27). There were four strains isolated in 
1989，1990 and 1992 which harboured a plasmid of 7.2 Kb. There were two 
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Table 27 Plasmid profiles of 63 aminoglycoside-resistant Ps. aeruginosa 
Plasmid No of isolates (%) 
No Size range (Kb) 
" " ^ r “ 2 (1) 
1 1 . 8 - > 221 28 (15) 
2 1.9- > 221 44 (23) 
3 1 . 3 - > 221 29 (15) 
4 1.2- > 221 22 (11) 
5 1.2- > 221 22 (11) 
6 1 . 2 - > 221 20 (10) 
7 1.2- > 221 11 (6) 
8 1.3- > 221 7 (4) 
9 1.2- 190 4 (2) 
10 3.4-151 1 (0) 
11 1.2- >221 3 (2) 
Total 193 (100) 
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^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 3 
• 
Figure 8 Plasmid profiles ofE. coli isolates. Lanes: 1-12 and 17-30 contain plasmids oiE. 
coli. Size markers are contained in lanes: 13, supercoiled DNA ladder; 14, 221 Kb; 
15; 119, 91 and 62 Kb; 16, 98 and 58 Kb. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
^ 1 
Figure 8-1 Plasmid profiles of E. coli isolates. Lanes: 1-13 and 18-30 contain plasmids of 
E. coli. Size markers are contained in lanes: 14，supercoiled DNA ladder; 15， 
221 Kb; 16, 119，91 and 62 Kb; 17，98 and 58 Kb. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
^ m • 
Figure 9 EcoRl digestion patterns of E. coli plasmids. Lanes: 1-10 contain plasmids 
of91 Kb, 12-16 contain plasmids of 119 Kb; 17-20 contain plasmids of 98 
Kb and 21-25 contain plasmids of 76 Kb. Lane 11 contains Hindlll digest 
of X DNA as the size marker. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
^ ^ ^ n 
• 
Figure 10 NindlII digestion patterns of E. coli plasmids. Lanes: 1-10 and 12-25 
contain plasmids as in Figure 9. Lanes 11 contains HindlW digest of X 
DNA as the size marker. 
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Table 27 Plasmid profiles of 63 aminoglycoside-resistant Ps. aeruginosa 
Plasmid No of isolates (%) 
No Size range (Kb) 
1 3 .1- > 221 9 (16) 
2 2.7 - > 221 25 (43) 
3 2.6 - > 221 13 (22) 
4 1.5 - > 221 10 (17) 
8 1.8-125 1 (2) 
^ ^ 58 (100) 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 
^ ^ m ^ ^ i 
Figure 11 Plasmid profiles of K. pneumoniae isolates. Lanes: 1-12 and 17-29 
contain plasmids of^K. pneumoniae. Size markers are contained in lanes: 
13, supercoiled DNA ladder; 14, 221 Kb; 15，119, 91 and 62 Kb; 16，98 
and 58 Kb. 
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Table 27 Plasmid profiles of 63 aminoglycoside-resistant Ps. aeruginosa 
Plasmid No of isolates (%) 
No Size range (Kb) 
0 - 48 (76) 
1 7.2 4 (6) 
1.3 -54 6 (10) 
2 1.4，1.5 2 (3) 
1.5, 1.6 2 (3) 
2.9, 119 1 (2) 
Total 63 (100) 
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strains each which harboured two plasmids of 1.4 and 1.5 Kb (isolated in 1992) 
and 1.5 and 1.6 Kb (isolated in 1991). The plasmid profiles are shown in 
figure 12. No plasmid band was observed in lanes 3，5-7, 10-12，18 and 22. 
E. Localization of aminoglycoside-resistance genes 
Of 78 AAC(3)-I- and AAC(3)-II-producing E. coli isolates tested, only 
30 (39%) could transfer their AME coding genes. Twelve of the 17 AAC(3)-I-
producing E. coli isolates tested harboured only one transferable plasmid while 
the other five harboured two or more (Tables 28 & 29). Eleven of the 
AAC(3)-II-producing strains harboured one transferable plasmid while two 
harboured two (Tables 28 & 29). The size of these plasmids were variable, 
ranging from 66 to 221 Kb (Tables 28 & 2¾. Transconjugants which gained 
the resistance plasmids from resistant E. coli isolates also produced AAC(3)-I 
or AAC(3)-II (Figures 13，13-1 & 13-¾. 
For those E. coli isolates which harboured transferable plasmids, 
resistance to gentamicin, tobramycin, netilmicin or sisomicin were transferable 
to recipient cells but resistance to streptomycin or spectinomycin was usually 
non-transferable. 
Of 54 K. pneumoniae randomly selected for study of the transferability 
of resistance plasmids, 33 (61%) could transfer their AME coding genes. 
Twenty-four could transfer one of their plasmids while nine could transfer two 
or more (Tables 30 & 31). The AME coding genes were located on plasmids 
of3.1 - > 221 Kb (Table 30; Figures 14 & 14-1). For strains which 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 
• 
Figure 12 Plasmid profiles of Ps. aeruginosa isolates. Lanes: 1-12 and 17-23 
contain plasmids of Ps. aeruginosa. Size markers are contained in 
lanes: 13，supercoiled DNA ladder; 14，221 Kb; 15, 119，91 and 62 
Kb; 16，98 and 58 Kb. No plasmid band is present in lanes 3，5-7, 10-
12，18 and 22. 
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Table 28 Resistance patterns and plasmid profiles of AAC(3)-I- and AAC(3)-II-
produdng Escherichia coli with one transferable resistance plasmid 
No Year Plasmid (Kb)^  Resistance pattern^ ^ME 
— i ^ " " 1 7 6 914.2 3.9 2.6 一 GTbS]sSSp AACX3)-I 
2 1898 > 2 2 T m 2 . 3 GSkSp ^^C^-J 
3 1990 82 GSisSp AAC(3)-I 
4 1990 7^59 3.9 GS^SSp A ^ ^ � ) - ; 
5 1990 156 89 4.2 3.9 2.6 G^SSp AAC(3)-I 
6 1990 119^ GSisSp 々々恐-; 
7 1990 189 U0 3.9 2.2 1.6 GS^SSp AAL(3)-i 
8 1990 >22125 GTbSkSp 八今恐1 
9 1991 9j^3.3 GSisSp AAC(3)-I 
10 1990 ^ 8 0 5.6 5.3 4.3 3.4 2.8 GNetSk AAC(3)-I 
11 1990 22J. 75 61 58 18 3.8 1.9 GSisSSp AAC(3)-I 
12 1990 H9 95 84 5.1 4.7 3.9 4.3 GSisSSp AAC(3)-I 
13 1989 U9 43 3.3 2.8 2.5 GTbNetSisS AAC(3)-II 
14 1990 m 82 4.2 3.3 2.8 GTbNetSisSp AAC(3)-II 
15 1990 m 9j. 3 1 GTbNetSisSSp AAC(3)-II 
16 1990 176五 GTbNetSisSSp AAC(3)-II 
17 1990 129^4.1 3.9 3.4 2.8 2.6 GTbNetSisSSp AAC(3)-II 
18 1990 194^4 .2 3.3 2.8 GTbNetSisSp AAC(3)-II 
19 1991 72219169 58 5.1 GTbNetSisSSp AACX3)-II 
20 1991 93 87 4；2 3.4 2.4 GTbSisSSp AAC(3)-II 
21 1991 m GTbNetSisSp AAC(3)-II 
22 1992 ^ 0 8.3 7.2 6.6 6.2 5 4.4 2.4 1.7 GNetSis AAC(3)-II 
23 1992 T ^ GTbNetSisSp AAC(3)-II 
1 Transferable plasmids are underlined. 
2 Resistances transferred are underlined. 
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Table 29 Resistance patterns and plasmid profiles of AAC(3)-I- and AAC(3)-II-producing 
Escherichia coli with more than one transferable resistance plasmid 
No Year Plasmid (Kb)^ Resistance pattern� AME 
24 1990 198 9J. GSisSp A A ^ ) - I 
25 1989 176 67 4.2 3.3 2.7 GSisSp AAC(3)-I 
26 1990 181 93 7.4 5.7 GSisSp AAC(3)-I 
27 1990 104 91 11 5.8 1.7 GTbSlsSp 八八匸⑶] 
28 1992 162,80 GSisLiv AAC(3)-I 
29 1991 m 72 57 7.2 5.3 4.3 3.4 2.3 GTbNetKSisRibSSp AAC(3)-II 
30 1992 U9 7156 5.6 4.9 4.4 3.8 3.4 3.3 2.8 GTbNetSisS AAC(3)-II 
1 Transferable plasmids are underlined. 
2 Resistances transferred are underlined. 
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• 
Figure 13 Agarose gel electrophoresis of plasmid DNA extracted from 
aminoglycoside-resistant E. coli and their transconjugants. Lanes: 
1，3，5, 7，9，11, 17，19，21，23，25 contain plasmids of E. coli and 
lanes: 2，4，6，8，10，12，18，20，22，24, 26 contain plasmids of 
their respective transconjugants. Size markers are contained in 
lanes: 13，supercoiled DNA ladder; 14，221 Kb; 15, 119，91 and 62 
Kb; 16，98 and 58 Kb. Lane 27 contains DNA extracted from 
Jp995, the recipient, which harbours no plasmid. 
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Figure 13-1 Agarose gel electrophoresis of plasmid DNA extracted from 
aminoglycoside-resistant E. coli and their transconjugants. Lanes: 
1，3，5, 7, 10，16，18，20, 22, 24，26 contain plasmids of E. coli 
and lanes: 2，4，6，8，9，17, 19，21，23, 25, 27 contain plasmids of 
their respective transconjugants. Size markers are contained in 
lanes: 11, supercoiled DNA ladder; 12，221 Kb; 13，119，91 and 62 
Kb; 14，98 and 58 Kb. Lane 15 contains DNA extracted from 
Jp995, the recipient, which harbours no plasmid. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
^^^1 
Figure 13-2 Agarose gel electrophoresis of plasmid DNA extracted from 
aminoglycoside-resistant E. coli and their transconjugants. Lanes: 
1, 3, 10, 12, 15, 17 contain plasmids oiE. coli and lanes: 2, 4，11, 
13，14, 16，18 contain plasmids of their respective transconjugants. 
Size markers are contained in lanes: 5, supercoiled DNA ladder; 6, 
221 Kb; 7, 119, 91 and 62 Kb; 8, 98 and 58 Kb. Lane 9 contains 
DNA extracted from Jp995, the recipient, which harbours no 
plasmid. 
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Table 30 Plasmid profiles of aminoglycoside-resistant Klebsiella pneumoniae isolates which 
have one transferable plasmid 
Strain Year Plasmid (Kb)* Resistance pattern^ AME^ 
No 
1 15^5~~>221 3.3 GTbKNSisLivRibSSp AAC(3)-II “ 
2 1990 >221 ^ GK^LivRibSSp AAC(3)-I 
3 1990 > 2 2 1 ~ G K ^ AAC(3)-II + AAD(9VI 
4 1989 U_ GTbNetKNSisLivRibS AAC(3)-II 
5 1990 21 GTbNetSp AAC(3)-II 
6 1990 T 2 2 i 65 GTbNetKSisLivRibSSp AAC(3VII 
7 1990 1 7 ^ 1 9 1 2 GTbNetKSp AAC(3)-II 
8 1989 > 2 2 1 ^ 3 . 7 3.6 GTbNetSisSSp AAC(3HI + APH(3”)-I 
9 1989 221 913.8 1.5 GNetSisSSp AAC(3)-II + APH(3")-I 
10 1989 > 2 2 1 9 1 3 . 8 1.4 GTbNetSisSSp AAC(3)-II+APH(3”)-I 
11 1989 1 9 8 ^ 3 . 9 1.5 GTbNetSisSSp AAC(3)-II + APH(3”)-I 
12 1989 1 9 8 ^ 3 . 9 1.5 GNetSisSp AAC(3)-II + APH(3")-I 
13 1989 198 ^ 3 . 9 1.5 GNetKLivRibSSp AAC(3VII + APH(3")-I 
14 1990 2 1 3 ^ GTbNetSisS AAC(3VII + APH(3")-I 
15 1992 T 2 2 i 1 4 6 ^ 4 . 6 GTbNetSisSp AACf3)-II + APH(3”H 
16 1992 176 91 GTbNetKNSisLivRibSSp AAC(3)-II + APH(3')-I 
17 1992 >22TlO3 GTbKNSisLivRibSSp AAC(3VII + APH(3>I 
18 1991 10323 2.8 GTbNetSisSp AAC(3)-II + AAD(9)-I 
19 1992 198 ^ 60 6.2 GTbKNSisLivRibS AAC(3)-II + APH(3，VII 
20 1990 ^ 2 2 1 GNetNSisLivS AAC(3HI + APH(3，)-I + APH(3 ”)-I 
21 1992 J ^ GTbKNSisLivRibSSp AAC(3)-II+APH(3，)-I+AAD(3 ” • 
22 1992 2 ^ 9 5 GTbKNSisLivRibSSp AAC(3)-II+APH(3^VI+APH(3")-I+AAD(6)-I 
23 1989 > 2 2 T i 9 8 GTbNetKNSisLivRibS AAC(3HI + APH(3，H + APHf3”VI 
24 1989 198 9 7 ^ GKNSisLivRib AAC(6]-II + APH(3，)-I + APH(3 ”)-I 
1 Transferable plasmids are underlined 
2 Resistances transferred are underlined 
3 AMEs produced by transconjugants are underlined 
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Table 31 Plasmid profiles of aminoglycoside-resistant Klebsiella pneumoniae 
isolates which have more than one transferable plasmid 
Strain Year Plasmid (Kb)^  Resistance pattern^ AME^ 
No 
25 1990 >221 88 GK^LivRibSSp AAC(3)-I 
26 1992 >221 92 GSisSp AAC(3H 
27 1989 102 91 GNetSisSp AAC(3VII4-AAD(9H 
28 1990 >221 65 GTbNetKSisLivRibSSp AAC(3)-II 
29 1990 22167 GTbNetKSisLivRibSSp AAC(3)-II 
30 1991 >221 111 4 2.7 GTbNetSisSSp AAC(3)-II 
31 1992 ^ h l GTbNetSisSSp AAC(3)-II 
32 1989 2 i ^ 2 ^ GNetKNSisLivRibSSp AAC(3)-II + APH(3")-1 
33 1990 187 98 80 GTbNetKNSisLivRibSSp AAC(3)-II + APH(3”)-I 
1 Transferable plasmids are underlined 
2 Resistances transferred are underlined 
3 AMEs produced by transconjugants are underlined 
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Figure 14 Agarose gel electrophoresis of plasmid DNA extracted from 
aminoglycoside-resistant K. pneumoniae and their transconjugants. 
Lanes: 1, 3，5, 7, 9, 11, 17，19, 21, 23, 25, 27 contain plasmids o£K 
pneumoniae and lanes: 2, 4, 6, 8, 10, 12, 18，20, 22, 24，26, 28 
contain plasmids oftheir respective transconjugants. Size markers are 
contained in lanes: 13，supercoiled DNA ladder; 14，221 Kb; 15，119, 
91 and 62 Kb; 16, 98 and 58 Kb. 
f 
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Figure 14-1 Agarose gel electrophoresis of plasmid DNA extracted from aminoglycoside-
resistant K. pneumoniae and their transconjugants. Lanes: 1，3, 5, 7, 9, 11, 13， 
19，21, 23, 25, 27 contain plasmids of K. pneumoniae and lanes: 2, 4, 6, 8, 10, 
12: 14: 20; 22; 24，26，28 contain plasmids of their respective transconjugants. 
Size markers are contained in lanes: 15，supercoiled DNA ladder; 16，221 Kb; 
17，119, 91 and 62 Kb; 18, 98 and 58 Kb. 
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produced two or more AMEs, the genes were located on the same plasmids. 
There were 18 strains which produced more than one AME but only had one of 
the plasmids transferred, indicating that the other AME genes were either 




The prevalence of aminoglycoside-resistance in Gram-negative bacteria 
in Hong Kong was high as compared to that in other parts of the world. 
There was an average of 18% E. coli, 10% Klebsiella sp, 16% Proteus sp, 
26% Enterobacters, 12% Ps, aeruginosa, 29% other Pseudomonas sp and 
48% Acinetobacter sp that were resistant to gentamicin. In the United 
Kingdom and United States, <3% and 5% of E. coli, respectively, were 
resistant to gentamicin (Phillips, King & Shannon, 1986; Gaynes et al., 1987; 
Spencer et al.，1990; MacGowan et al” 1993) and the corresponding figure 
in Austria was 2-6% (Mittermayer et al., 1990). There was also a significant 
increase in the incidence of gentamicin-resistant bacteria from 1990 to 1992. 
However, it is difficult to attribute the high incidence of resistance to the 
usage of aminoglycoside in this hospital as such information is lacking. 
Studies on the relationship between the use of antibiotics and the development 
of resistance have been controversial and conflicting. Some workers showed 
that increased usage of amikacin led to an increase in the incidence of 
resistance to this drug (Levine et al., 1985; Hammerberg et al., 1986; Maes 
& Vanhoof，1992). Other investigators reported that there was no correlation 
between increased amikacin usage and increased resistance (Price et al., 
1981; Powell & Pincus, 1987; Vanhoof et al., 1988). Such conflicting 
results are due to the many other factors that contribute to this phenomenon, 
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results are due to the many other factors that contribute to this phenomenon, such 
as the concomitant use of different classes of antibiotics, the spread of antibiotic-
resistant organisms and the association of extensive use of and emergence of 
resistance to totally different antibiotics (Goldstein et al., 1983; Young & 
Hindler, 1986; Sirot et aL, 1988; Maes & Vanhoof, 1992). 
Tobramycin had similar activity as gentamicin as revealed by the similar 
proportion of isolates that were resistant to these two aminoglycosides (19% E. 
coli, 10% Klebsiella sp, 10% Proteus sp, 29% Enterobacters, 8% Ps. 
aeruginosa, 26% other Pseudomonas sp and 28% Acinetobacter sp). This result 
supports the fact that tobramycin is similar to gentamicin with respect to 
effectiveness in treating infections caused by susceptible organisms (Lietman, 
1990). 
Netilmicin was much more active as only <8% of E. coli, Klebsiella sp, 
Proteus sp or Ps. aeruginosa were resistant. Other Pseudomonas sp, 
Acinetobacter sp and Enterobacters were the most resistant of the Gram-
negatives, with 16%-30% being resistant. In contrast to the increase in incidence 
of gentamicin- or tobramycin-resistant isolates from 1990 to 1992，there was a 
decrease in the incidence of netilmicin-resistance during the same period in 
almost all of the Gram-negatives. Since netilmicin has only recently been 
extensively used in place of gentamicin in this hospital, the decrease in the level 
of netilmicin-resistance is probably due to the higher activity of the drug and the 
concomitant increased usage of cephalosporins (unpublished observation). 
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Amikacin was the most active of the aminoglycosides against the 
enterobacteria although there was a substantial proportion (26%) of 
Pseudomonas sp other than Ps. aeruginosa that were resistant. There was 
also a general decline in the level of resistance to this aminoglycoside. 
Presumably, amikacin-resistant organisms were introduced into this hospital 
by patients, thereby resulting in some fluctuation in the level of resistance. 
Due to good infection control practices of our hospital, these resistant isolates 
did not spread and the incidence was controlled to a very low level. 
In general, we found that enterobacteria were mostly more sensitive to 
gentamicin, tobramycin or netilmicin than non-fermenters as reported by 
others (Naber et al., 1990; Boisivon et al., 1992). These investigators 
showed that resistance rates were usually <5% for enterobacteria while those 
for the non-fermenters were usually > 10%. However, such resistance rates 
varied amongst organisms from different countries. In a study from Italy, up 
to 37% of the enterobacteria were resistant to either gentamicin or 
tobramycin (Toscano et aL, 1991). In Greece, >70% of Enterobacter 
cloacae were resistant to aminoglycosides (Vatopoulos et aL, 1992). 
Organisms isolated from different specimens might also have different levels 
of resistance. Naber and colleagues (1990) showed that Pseudomonas sp 
isolated from urines were more resistant than those isolated from blood 
cultures. 
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With respect to the MICs of different aminoglycosides to 
aminoglycoside-resistant E. coli and K. pneumoniae tested, gentamicin had 
the highest MIC90 (128 mg/L) amongst tobramycin, netilmicin and amikacin, 
indicating that isolates were usually resistant to high concentrations of 
gentamicin while those that were resistant to the other three aminoglycosides, 
the level of resistance was usually lower. Taking the BSAC breakpoint of 1 
mg/L for gentamicin, tobramycin and netilmicin, similar proportions were 
resistant (83-100%) while the NCCLS breakpoint of 4 mg/L delineated a 
varied proportion of resistant isolates (31-100%). In contrast, MIC90S of 
these three aminoglycosides to Ps. aeruginosa were similar (>128 mg/L) and 
that a similar proportion of isolates were resistant to either 1 mg/L or 4 
mg/L. This shows that most E. coli and K. pneumoniae could be inhibited by 
a lower concentration of these drugs while Ps. aeruginosa could only be 
inhibited by a much higher concentration. Similarly, most E. coli and K. 
pneumoniae (99%) could be inhibited by 16 mg/1 amikacin while up to 20% 
of Ps. aeruginosa were resistant. 
Few studies have reported the MICs of different aminoglycosides to 
aminoglycoside-resistant organisms tested. Most investigations based on the 
resistance breakpoint method (Dornbusch et al., 1990) or disc diffusion test 
(Maes & Vanhoof，1992; Boisivon et al” 1992; Vatopoulos et al., 1992) to 
determine the prevalence of resistance. It would be difficult to compare the 
resistance mechanisms from different studies based on results obtained by 
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such methods unless attempt was made to characterize the AMEs. Since 
some AMEs conferred low level resistance to particular aminoglycosides so 
that organisms producing an AME might not be resistant to an 
aminoglycoside and that some AMEs expressed to different levels in different 
organisms, a more complete investigation of the resistance mechanism should 
include determination of MICs and characterization of AMEs. 
For aminoglycosides that were not clinically used, butirosin was the 
most active against E. coli and K. pneumoniae while 67-100% ofPs. 
aeruginosa were resistant. From this resistance profile, it would not be 
surprising to find that AMEs produced by E. coli and K. pneumoniae were 
considerably different from those produced by Ps, aeruginosa. This will be 
discussed further later. 
Ninety-eight percent of E. coli or K, pneumoniae were resistant to 
three or more aminoglycosides while all Ps, aeruginosa were resistant to at 
least seven aminoglycosides. Most isolates that were resistant to tobramycin 
or netilmicin were also resistant to gentamicin. Thus, most aminoglycoside-
resistant isolates were multiply-resistant and that the choice of an antibiotic in 
treating such infections would be limited to amikacin or another class of 
antibiotics. 
B. Mechanisms of aminoglycoside-resistance 
Acetylating enzymes especially AAC(3)-I were commonly produced by 
E. coli and K. pneumoniae but rarely by Ps. aeruginosa. AAC(3)-I confers 
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resistance to gentamicin and sisomicin and can be deduced from the resistance 
profile of organisms that produce this enzyme. As less isolates were resistant 
to tobramycin or netilmicin than to gentamicin, it is not surprising to find that 
AAC(3)-II was second to AAC(3)-I in frequency since AAC(3)-II confers 
resistance to gentamicin, tobramycin, netilmicin and sisomicin. The 
commonest enzyme responsible for streptomycin-resistance which was 
prevalent amongst these three organisms was APH(3,,)-I while AAD(3")(9) 
and AAD(6)-I were rare. E. coli, K. pneumoniae and Ps. aeruginosa isolates 
producing multiple enzymes were also common since most of them were 
resistant to multiple aminoglycosides. 
APH enzymes other than APH(3")-I found amongst the isolates tested 
were mainly APH(3')-I which confers resistance to kanamycin or neomycin. 
Various other APH(3')-type enzymes were also produced by Ps. aeruginosa 
but not by E, coli or K. pneumoniae. These enzymes differ mainly in the 
ability to modify lividomycin, ribostamycin or butirosin. Since Ps. 
aeruginosa differed from E. coli and K. pneumoniae in being more resistant 
to these three aminoglycosides, it is not surprising to find that a more varied 
APH-type enzymes were produced by Ps. aeruginosa. The presence of such 
APH enzymes would not affect significantly the choice of aminoglycoside 
therapy since they usually confer resistance to less clinically-important 
aminoglycosides. Adenylating enzymes were rarely produced by the isolates 
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tested especially E. coli (8%) and these were mainly the streptomycin-
hydrolysing enzymes. 
The types of AMEs produced by E. coli and K. pneumoniae were quite 
different from those produced by Ps. aeruginosa. The former two organisms 
commonly produced AAC-type while Ps. aeruginosa commonly produced 
APH-type enzymes. Such difference could probably be due to limited genetic 
exchange between Pseudomonas sp and other Gram-negative bacteria 
(Aminoglycoside Resistance Study Group, 1994). 
There were similarities and differences of the types of AMEs found 
amongst Gram-negatives isolated in Hong Kong and in other parts of the 
world. AAC(3)-I and AAC(3)-II enzymes were in general the predominant 
enzymes found in this locality and elsewhere (Phillips, King & Shannon, 
1986; Navarova et aL, 1989; Shaw et al.，1991; Maes & Vanhoof，1992). 
However, we have much less adenylating enzymes in types and prevalence. 
Presumably, genes coding for these enzymes were located on the 
chromosome so that they did not spread rapidly. APH-type enzymes detected 
in this study were also different from those found elsewhere. Shaw and 
colleagues (1991) noted that, by using specific DNA probes, the frequency of 
resistance genes varied in different countries. This could be explained by the 
fact that a gene could become associated with a transferable plasmid or 
transposon and thus became endemic while the same might not happen to the 
gene in another country, resulting in differences in the prevalence of a gene 
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in different localities. The frequency of some resistances could also vary for 
different organisms (Shaw et al.，1991). If genes coding for the resistances 
were chromosomally located or were expressed in a particular bacterial 
species, then the genes were likely to remain in a particular species. If the 
gene was located on a transferable plasmid or transposon and could be 
expressed in many host strains, then the gene could spread and be found in 
many different organisms. 
The Aminoglycoside Resistance Study Groups (1994) reported that 
26% of 1258 aminoglycoside-resistant Pseudomonas sp tested had 
permeability changes which were defined as resistance to gentamicin, 
tobramycin, netilmicin, amikacin and isepamicin. Although we did not test 
isepamicin, there were 11 Ps. aeruginosa isolates (15%) that were resistant to 
all 12 aminoglycosides and only two of these produced gentamicin-
hydrolysing enzymes. Thus, these isolates probably also had changes in their 
cell wall permeability which led to resistance to multiple aminoglycosides. 
AAC(6,)_ or AAC(3)-type enzymes accounted for up to 70% or more 
of aminoglycoside-resistance in Ps. aeruginosa (Shimizu et al., 1985; 
Phillips, King & Shannon，1986; Aminoglycoside Resistance Study Groups, 
1994). However, we could detect acetylating enzymes in very few of our Ps. 
aeruginosa isolates. This is difficult to explain as all were resistant to either 
gentamicin or netilmicin. Presumably these isolates had permeability changes 
which spared amikacin. 
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c. Genetic location of aminoglycoside-resistance and plasmid profiles 
Only 39% of 30 E. coli isolates tested could transfer their 
aminoglycoside-resistances. Transfer studies were performed in batches 
when at least five isolates were tested per batch. In each batch, there were 
isolates which transferred their resistances as well as those which did not 
transfer resistances. Thus, those in which transferable resistances were not 
detected represented a true phenomenon rather than an experimental error. 
Twenty-three isolates had their resistances borne on a plasmid of 82 - 221 Kb 
(Table 28) while seven had their resistances borne on two or more plasmids 
o f5 .8 - 198 Kb (Table 29). Either only one of these plasmids was 
transferable which acted as a transfer factor and mobilized the other non-
transferable plasmids within the isolates or that all the plasmids were 
transferable. However, it would not be possible to locate the resistances on 
the individual plasmids unless they were separated by agarose gel 
electrophoresis and the individual plasmids used to transform an E. coli 
recipient. If the transformed E. coli containing only one plasmid became 
resistant to the aminoglycosides to which the plasmid-harbouring donor was 
resistant and produced the same AME as that produced by the donor, then the 
resistance gene could be located on the plasmid. Alternatively, we could use 
specific gene probes to hybridize with the plasmids. 
Almost all our E. coli isolates (99%) harboured plasmids. The 
plasmid profile with respect to number and size was different in all plasmid-
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harbouring strains. Although plasmids of 76, 91，98 and 119 Kb were found 
in more than one isolate, they were not identical as they produced different 
restriction fragments after digestion with EcoKl or HinAlW. E, coli isolates 
producing the same type of AMEs also had different plasmid profiles. Thus, 
these isolates belonged to different clones and there was no obvious outbreak 
of aminoglycoside-resistant E. coli within the hospital. 
Genes coding for the production of AMEs in K. pneumoniae were 
usually borne on transferable plasmids. All these plasmids were >80 Kb in 
size except for one which was 3.1 Kb (Tables 30 & 31). There were nine 
isolates which transferred aminoglycoside-resistances but more than one 
plasmid were found in the transconjugants. Similar to the situation seen in E. 
coli，it would not be possible at the moment to determine the location of 
resistance genes on a specific plasmid and further experiments such as those 
described above would be required to elucidate this. 
Plasmid profiles of K. pneumoniae were also very varied with no 
predominance of a particular profile. There was no particular plasmid that 
was found in more than two isolates and that isolates producing the same 
AMEs had different plasmid profiles. Thus, there also was no outbreak of 
aminoglycoside-resistant K. pneumoniae within the hospital and isolates were 
of a very heterogenous group. 
It would be desirable to compare the epidemiological data of patients 
from whom isolates were obtained, however, it would be difficult if not 
123 
impossible to do in such a retrospective study. Only age and sex of patients 
were entered into the computer while other information such as the location 
from which the patient was admitted, what antibiotics the patient had been on 
before resistant organisms were isolated, the duration of stay in the hospital, 
etc, could only be retrieved from case notes of patients. In order to include a 
more representative group of isolates, we randomly selected approximately 
equal proportion of isolates from each of the four years of 1989-1992. 
Isolates from different years produced similar types of AMEs with no 
predominance of a type in a particular year (data not shown). 
Resistance to gentamicin, tobramycin, netilmicin or sisomicin of K. 
pneumoniae was usually transferable and such resistances were due to 
AAC(3)-I or AAC(3)-II enzyme. For those isolates which produced AAC(3)-
I but were resistant to tobramycin or netilmicin, such resistance was usually 
of a low level and not transferable, indicating that AAC(3)-I was not 
responsible for the resistance. Presumably there were some permeability 
changes of the cell membrane of these isolates which led to a higher MICs of 
tobramycin or netilmicin. Resistance to streptomycin or spectinomycin in 
these isolates was also of a low level and not transferable, again confirming 
the finding that donor strains did not produce AMEs responsible for the 
modification of these drugs and other factors such as permeability changes 
might be responsible for the resistances. 
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In contrast to E. coli and K. pneumoniae, only 34% of 63 Ps. 
aeruginosa isolates tested harboured plasmids. Although four isolates 
harboured plasmids of 12 Kb and two isolates each of which harboured 1.5 
and 1.4 Kb, and 1.6 and 1.5 Kb plasmids, it would be difficult to prove their 
identity by restriction enzyme digestion because of their small size. Other 
molecular methods such as ribotyping or random amplified polymorphic 
DNA analysis would be required to prove whether these and the plasmidless 
isolates were identical or not. 
Presumably, genes coding for AAC(3)-I and AAC(3)-II which were 
commonly produced by E. coli and K, pneumoniae were borne on 
transposons or, as shown in this study, on transferable plasmids. These 
resistant strains served as a gene pool from which other sensitive strains 
might acquire the resistance genes. Thus the same genes could be found in 
different clones of the same or different species due to gene transfer. These 
strains were of different clones as shown by their very different plasmid 
profiles. The genes were probably present on transposons because genes 
coding for the same AME were located on plasmids of different sizes or, 
when they could not be transferred from one strain to another, on non-
transferable plasmids or chromosome. 
AMEs produced by Ps. aeruginosa were quite different from those 
produced by E. coli or K. pneumoniae probably because there was no genetic 
exchange between the former and the latter two organisms as discussed 
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previously. However, there might be genetic exchange amongst Ps. 
aeruginosa strains. Genes coding for AMEs might be located on plasmids, 
transposons or the chromosome and further studies such as transfer, 
transformation or DNA-DNA hybridization studies would be required to 
determine the exact location of these genes. 
D. Characterization of AMEs 
The simplest method used for identification of the types of A M E was 
determination of resistance profiles, ie, the aminoglycosides to which the 
AME-producing organisms were resistant or susceptible. As mentioned 
previously, most studies used disk diffusion test for the purpose which is less 
satisfactory than agar or broth dilution test. Besides, this method cannot 
distinguish two AMEs produced by the same isolate if they have overlapping 
resistance profiles. In this study, we found that characterization by the 
phosphocellulose paper binding assay was more satisfactory. However, the 
procedures involved are very tedious, time-consuming, expensive and 
radioisotopes have to be used. Although seven isolates could be tested using 
one 96-well microtitre plate, only five clinical isolates were assayed since a 
positive and negative control strain had to be included in every plate. The 
maximum number of isolates that could be tested for one type of enzyme per 
day would only be 20，assuming that the counting of radioactivity was 
performed overnight. Isolates that gave negative results were assayed again 
or enzyme extraction repeated to rule out false negativity. During the initial 
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phase of the study, many isolates gave negative results due to insufficient 
enzyme. The volume of broth culture was therefore stepped up to produce 
more cells and thus more enzymes. Extra care had to be taken to prevent 
cross-contamination of wells. Whenever spurious substrate profiles were 
obtained, the assay had to be repeated. It was found that pipetting had to be 
done slowly to prevent such cross-contamination. Other laborious work 
involved the cutting into squares of phosphocellulose paper and then labelling 
them, the putting of these squares into scintillation vials and then filling them 
up with scintillation fluid. All these contributed to the tremendous amount of 
time and effort that had to be spent to produce reliable results. 
Recently, gene probes had been developed and used in hybridizing 
with DNA of resistant organisms. The main disadvantage of this method is 
that the same AME can be coded for by different genes (Shaw et al., 1993a). 
Thus, the identity of AME has to be first determined by the phosphocellulose 
paper binding assay and then confirmed by probing with available probes. A 
negative result may mean incorrect identification by the assay or that a new 
gene encodes the AME. 
Polymerase chain reaction (PCR) had recently been developed to detect 
genes coding for four AAC(3)-type enzymes that were prevalent in Gram-
negative bacteria (Vliegenthart, Ketelaar-van Gaalen & van de Klundert, 
1990) as well as those circulating amongst Gram-positive cocci (Ounissi et 
al.，1990). van de Klundert and Vliegenthart (1993) developed and chose 
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primers in such a way that each gene coding for an AME yielded a fragment 
of different length so that in one PCR, four genes in one single strain could 
be detected. The amplified product was digested with a restriction enzyme to 
check the specificity of the amplification reaction. 
In summary, we have found that aminoglycoside-resistance remains an 
important problem amongst Gram-negative bacteria in Hong Kong. Most of 
the resistant isolates were resistant to multiple aminoglycosides except 
amikacin, thereby limiting the choice of effective antimicrobial therapy. The 
organisms belonged to a very heterogenous group with no particular clone 
predominating. They were resistant due to production of AMEs mainly of 
the AAC(3)-type or APH(3")-type, some of the encoding genes being borne 
on transferable plasmids of different sizes. There appeared to be no outbreak 
of aminoglycoside-resistant isolates and they seemed to be acquired 
sporadically. 
E. Areas for future research 
In view of the importance of aminoglycoside-resistance in Hong Kong, 
continuous surveillance of these isolates should be carried out to monitor their 
development of resistance especially to amikacin which is the only effective 
aminoglycoside for therapy. Since enteric organisms are frequently reservoir 
of resistance genes which can be transferred to other bacteria, it is important 
that efforts be made to control the spread of these resistant bacteria whenever 
they are isolated. Although p-lactam drugs are preferred to aminoglycosides 
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because of their fewer side-effects, the prevalence of isolates which are 
resistant to the third generation cephalosporins is increasing all over the 
world (Sirot et al., 1988; Garau, 1994). Thus aminoglycosides still have its 
place in chemotherapy. 
It is important to study the mechanisms of aminoglycoside-resistance in 
order to follow the spread of resistance genes, which resistance genes are on 
the increase and where these genes are present. However, as the 
phosphocellulose paper binding assay is a tedious and time-consuming method 
and involves radioisotopes, it is not suitable for routine detection of AMEs. 
Hybridization using specific DNA probes is an alternative, however, it is also 
not a rapid method. The use of polymerase chain reaction can be developed 
for this purpose. As our study has shown the types of AMEs that are 
prevalent in Hong Kong, we can use this as a basis for the selection of 
primers for amplification of resistance genes. 
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Buffers and Stock solutions 
1. Plasmid extraction 
Stock solutions 
• Lysing solution (Kado and Liu, 1981) 
3 % Sodium dodecyl sulphate (SDS) 
50 mM Tris 
Adjust to pH 12.6 with 3N NaOH 
• STE buffer (pH 8) 
10 mM NaCl 
10 mM Tris.Cl (pH 7.5) 
1 mM EDTA (pH 8) 
• Solution I 
50 mM glucose 
25 mM Tris.Cl 
10 mM EDTA (pH8) 
• Solution II 
0.2 N NaOH 
1 % SDS 
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APPENDEX (Cont'd) 
Buffer and Stock solutions 
• Solution III 100 ml 
5 M postassium acetate 60 ml 
Glacial acetic acid 11.5 ml 
Distilled water 28.5 ml 
2 Enzyme extraction buffer 
Tris (Hydroxymethyl)-aminomethane 2 ml 
Ammonium chloride 1.25 ml 
Magnesium chloride 6 ml 
Distilled water 15 ml 
Adjust the pH to 7.8 by adding drop by drop of 1 M malicid acid. Add distilled 
water to a final volume of 30 ml. Dithiothreitol is added to the buffer solution to 
achieve a final concentration of 5 mM immediately before use. 
3 Agarose gel electrophoresis 
• Electrophoresis buffer 10X 1000 ml 
108 g Tris base 
0.5 M EDTA (pH 8) 40 ml 
• Loading buffer 6X 
0.25% bromophenol blue 
15% Ficoll type 400 
• Ethidium bromide 10 mg/ml 
Dissolve 0.5 g ethidium bromide in 50 ml distilled water. Stir for several hours 
on a magnetic stirrer to ensure that the dye is completely dissolved. Wrap the 
container with aluminum foil and store at 4°C. 
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